var title_f9_44_9920="Choroidal tuberculosis";
var content_f9_44_9920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Choroidal tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Miliary choroids (tubercles) appear as ill-defined nodules varying in size from pinpoint to several disc diameters on funduscopic examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Copyright &copy; American Society of Contemporary Ophthalmology. Annals of Ophthalmology 1989.21(6);226.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9920=[""].join("\n");
var outline_f9_44_9920=null;
var title_f9_44_9921="Ketazolam: International drug information";
var content_f9_44_9921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketazolam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anseren (IT);",
"     </li>",
"     <li>",
"      Ansieten (AR);",
"     </li>",
"     <li>",
"      Ansietil (CL);",
"     </li>",
"     <li>",
"      Marcen (ES);",
"     </li>",
"     <li>",
"      Sedatival (CL);",
"     </li>",
"     <li>",
"      Sedotime (ES);",
"     </li>",
"     <li>",
"      Solatran (BE, CH, ZA);",
"     </li>",
"     <li>",
"      Unakalm (NL, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2529499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2529500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anxiety, tension, irritability, and similar stress related symptoms",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2529502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 15-60 mg/day in a single dose or divided doses taken prior to bedtime; usual dosage: 30 mg/day prior to bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in the elderly and debilitated patients:",
"     </b>",
"     Lower dose should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2529503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 15 mg, 30 mg, 45 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10468 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9921=[""].join("\n");
var outline_f9_44_9921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369824\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529499\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529500\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529502\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821107\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529503\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9922="Calabar swelling";
var content_f9_44_9922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Calabar swelling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9922=[""].join("\n");
var outline_f9_44_9922=null;
var title_f9_44_9923="Basic ECG test";
var content_f9_44_9923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic ECG test",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9923/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9923/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9923/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9923/contributors\">",
"     David M Mirvis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9923/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9923/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/44/9923/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 45 year-old black man is noted to have a blood pressure of",
"    <span class=\"nowrap\">",
"     150/100.",
"    </span>",
"    He has been hypertensive for at least 10 years. What abnormality is shown on the electrocardiogram (",
"    <a class=\"graphic graphic_waveform graphicRef67153 \" href=\"UTD.htm?42/0/43018\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef56197 \" href=\"UTD.htm?8/42/8873\">",
"     waveform 2",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the cause of the wide QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef63895 \" href=\"UTD.htm?42/11/43194\">",
"     waveform 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef75642 \" href=\"UTD.htm?12/60/13257\">",
"     waveform 4",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the cause of the patient's rapid, irregular pulse (",
"    <a class=\"graphic graphic_waveform graphicRef54703 \" href=\"UTD.htm?3/50/3879\">",
"     waveform 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef66491 \" href=\"UTD.htm?23/8/23682\">",
"     waveform 6",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient complains of \"extra\" beats. What is the arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef79389 \" href=\"UTD.htm?14/48/15112\">",
"     waveform 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef57503 \" href=\"UTD.htm?9/47/9973\">",
"     waveform 8",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef69277 \" href=\"UTD.htm?23/58/24485\">",
"     waveform 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef79105 \" href=\"UTD.htm?2/14/2272\">",
"     waveform 10",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient complains of palpitations. What is the arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef60015 \" href=\"UTD.htm?17/53/18263\">",
"     waveform 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef71816 \" href=\"UTD.htm?6/43/6835\">",
"     waveform 12",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following electrocardiogram is obtained during a cardiac arrest. What is the arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef81899 \" href=\"UTD.htm?35/62/36838\">",
"     waveform 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef58471 \" href=\"UTD.htm?38/6/39009\">",
"     waveform 14",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CASE 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the cause of the patient's rapid, irregular pulse (",
"    <a class=\"graphic graphic_waveform graphicRef73763 \" href=\"UTD.htm?23/2/23591\">",
"     waveform 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef52763 \" href=\"UTD.htm?17/13/17619\">",
"     waveform 16",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CASE 9",
"    </span>",
"    &nbsp;&mdash;&nbsp;How does the rhythm change abruptly in this patient (",
"    <a class=\"graphic graphic_waveform graphicRef64545 \" href=\"UTD.htm?40/54/41829\">",
"     waveform 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef72250 \" href=\"UTD.htm?19/4/19520\">",
"     waveform 18",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CASE 10",
"    </span>",
"    &nbsp;&mdash;&nbsp;What arrhythmia and what conduction disturbance are present in this lead V1 rhythm strip (",
"    <a class=\"graphic graphic_waveform graphicRef82285 \" href=\"UTD.htm?36/38/37478\">",
"     waveform 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef62199 \" href=\"UTD.htm?40/44/41665\">",
"     waveform 20",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CASE 11",
"    </span>",
"    &nbsp;&mdash;&nbsp;What arrhythmia is present in this patient (",
"    <a class=\"graphic graphic_waveform graphicRef73988 \" href=\"UTD.htm?16/19/16694\">",
"     waveform 21",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef82531 \" href=\"UTD.htm?2/39/2673\">",
"     waveform 22",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CASE 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 50 year-old man presents with chest discomfort. The electrocardiogram is most consistent with which diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef60739 \" href=\"UTD.htm?42/52/43850\">",
"     waveform 23",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef72407 \" href=\"UTD.htm?11/46/12010\">",
"     waveform 24",
"    </a>",
"    )?",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute inferolateral myocardial infarction",
"     </li>",
"     <li>",
"      Acute pericarditis",
"     </li>",
"     <li>",
"      Prinzmetal's angina",
"     </li>",
"     <li>",
"      Normal variant \"early repolarization\"",
"     </li>",
"     <li>",
"      Ventricular aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CASE 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 63 year-old woman had severe chest pain six hours ago. What does the electrocardiogram show (",
"    <a class=\"graphic graphic_waveform graphicRef51524 \" href=\"UTD.htm?42/16/43274\">",
"     waveform 25",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63253 \" href=\"UTD.htm?17/5/17497\">",
"     waveform 26",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CASE 14",
"    </span>",
"    &nbsp;&mdash;&nbsp;What conduction disturbance is present (",
"    <a class=\"graphic graphic_waveform graphicRef70922 \" href=\"UTD.htm?42/26/43434\">",
"     waveform 27",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef53626 \" href=\"UTD.htm?24/14/24809\">",
"     waveform 28",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CASE 15",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 58 year-old man had severe substernal chest pain two days ago. What abnormality is shown on the electrocardiogram (",
"    <a class=\"graphic graphic_waveform graphicRef65389 \" href=\"UTD.htm?1/48/1802\">",
"     waveform 29",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef77122 \" href=\"UTD.htm?20/34/21032\">",
"     waveform 30",
"    </a>",
"    )?",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2100 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9923=[""].join("\n");
var outline_f9_44_9923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CASE 8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CASE 9",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CASE 10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CASE 11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CASE 12",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CASE 13",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CASE 14",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CASE 15",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2100|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/0/43018\" title=\"waveform 1\">",
"      Basic case 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/42/8873\" title=\"waveform 2\">",
"      Basic case 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/11/43194\" title=\"waveform 3\">",
"      Basic case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/60/13257\" title=\"waveform 4\">",
"      Basic case 2 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?3/50/3879\" title=\"waveform 5\">",
"      Basic case 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/8/23682\" title=\"waveform 6\">",
"      Basic case 3 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/48/15112\" title=\"waveform 7\">",
"      Basic case 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?9/47/9973\" title=\"waveform 8\">",
"      Basic case 4 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/58/24485\" title=\"waveform 9\">",
"      Basic case 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?2/14/2272\" title=\"waveform 10\">",
"      Basic case 5 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/53/18263\" title=\"waveform 11\">",
"      Basic case 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/43/6835\" title=\"waveform 12\">",
"      Basic case 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?35/62/36838\" title=\"waveform 13\">",
"      Basic case 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/6/39009\" title=\"waveform 14\">",
"      Basic case 7 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/2/23591\" title=\"waveform 15\">",
"      Basic case 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/13/17619\" title=\"waveform 16\">",
"      Basic case 8 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/54/41829\" title=\"waveform 17\">",
"      Basic case 9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/4/19520\" title=\"waveform 18\">",
"      Basic case 9 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/38/37478\" title=\"waveform 19\">",
"      Basic case 10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/44/41665\" title=\"waveform 20\">",
"      Basic case 10 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/19/16694\" title=\"waveform 21\">",
"      Basic case 11",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?2/39/2673\" title=\"waveform 22\">",
"      Basic case 11 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/52/43850\" title=\"waveform 23\">",
"      Basic case 12",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/46/12010\" title=\"waveform 24\">",
"      Basic case 12 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/16/43274\" title=\"waveform 25\">",
"      Basic case 13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/5/17497\" title=\"waveform 26\">",
"      Basic case 13 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/26/43434\" title=\"waveform 27\">",
"      Basic case 14",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/14/24809\" title=\"waveform 28\">",
"      Basic case 14 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?1/48/1802\" title=\"waveform 29\">",
"      Basic case 15",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/34/21032\" title=\"waveform 30\">",
"      Basic case 15 with answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9924="Agalsidase alfa: Patient drug information";
var content_f9_44_9924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Agalsidase alfa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38867?source=see_link\">",
"     see \"Agalsidase alfa: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4803323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Replagal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691839",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Fabry disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to agalsidase alfa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs while this drug is being given. These include headache, weakness, fever, shakes, aches, pains, and sweating. You may be given drugs before this shot to avoid these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure during infusion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11013 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.179.173.170-A48E13D4B1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9924=[""].join("\n");
var outline_f9_44_9924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803323\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021153\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021155\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021154\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021159\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021160\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021162\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021157\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021158\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021163\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021164\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38867?source=related_link\">",
"      Agalsidase alfa: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9925="Halobetasol: Drug information";
var content_f9_44_9925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Halobetasol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/35/24116?source=see_link\">",
"    see \"Halobetasol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/37/43603?source=see_link\">",
"    see \"Halobetasol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halonate&trade;;",
"     </li>",
"     <li>",
"      Ultravate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ultravate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F178411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Topical: Apply sparingly to skin once or twice daily, rub in gently and completely; treatment should not exceed 2 consecutive weeks and total dosage should not exceed 50 g/week. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F178418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/37/43603?source=see_link\">",
"      see \"Halobetasol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F178412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultravate&reg;: 0.05% (15 g [DSC], 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as propionate: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Halonate&trade;: 0.05% (50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultravate&reg;: 0.05% (15 g [DSC], 50 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F178396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Not for ophthalmic use. Use of occlusive dressings is not recommended. Apply thin film to affected area and rub in completely. Do not apply to the face, groin, or axillae.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of inflammatory and pruritic manifestations of corticosteroid-response dermatoses [super high potency topical corticosteroid]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ultravate&reg; may be confused with Cutivate&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Intracranial hypertension (systemic effect reported in children treated with topical corticosteroids)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching (4%), acneiform eruptions, allergic contact dermatitis, dry skin, erythema, folliculitis, hypertrichosis, hypopigmentation, leukoderma, miliaria, perioral dermatitis, pruritus, pustulation, rash, skin atrophy, skin infection (secondary), striae, telangiectasia, vesicles, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine: Glycosuria, HPA axis suppression, metabolic effects (hyperglycemia, hypokalemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning (2% to 4%), stinging (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to halobetasol or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F178384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation. Discontinue therapy if irritation develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Perioral dermatitis: Should not be used for the treatment of perioral dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rosacea: Should not be used for the treatment of rosacea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin infections: Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; discontinue halobetasol treatment if infection does not resolve promptly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for ophthalmic use. Not recommended for application to the face, groin, or axillae.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F178402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F178413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F178403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemically administered corticosteroids appear in human milk and may cause adverse effects in a nursing infant. It is not known if the systemic absorption of topical halobetasol results in detectable quantities in human milk. Use with caution while breast-feeding; do not apply to nipples (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F178401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Halobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $31.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Ultravate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $212.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Halonate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 &amp; 12%(foam) (163.4 g): $262.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Halobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $31.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Ultravate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $212.61",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13843143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess HPA axis suppression in patients using potent topical steroids applied to a large surface area or to areas under occlusion (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F178383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids inhibit the initial manifestations of the inflammatory process (ie, capillary dilation and edema, fibrin deposition, and migration and diapedesis of leukocytes into the inflamed site) as well as later sequelae (angiogenesis, fibroblast proliferation)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F178398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Percutaneous absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings; &lt;6% of a topically applied dose enters circulation within 96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/44/9925/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menter A, Korman NJ, Elmets CA, et al, &ldquo;Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis. Section 3. Guidelines of Care for the Management and Treatment of Psoriasis With Topical Therapies,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2009, 60(4):643-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/44/9925/abstract-text/19217694/pubmed\" id=\"19217694\" target=\"_blank\">",
"        19217694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/44/9925/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8514 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9925=[""].join("\n");
var outline_f9_44_9925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178410\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178422\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178411\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178418\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178412\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178393\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178396\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178394\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178429\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178420\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178399\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178384\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299435\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178389\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178390\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178402\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178413\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178403\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178401\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13843143\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178383\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178398\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8514|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/35/24116?source=related_link\">",
"      Halobetasol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/37/43603?source=related_link\">",
"      Halobetasol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9926="Nephrology pattern 15 answer";
var content_f9_44_9926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 15 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal atheroembolus. Light micrograph of an atheroembolus in a muscular renal artery showing cleft-like spaces (arrow) due to washout of the cholesterol crystals during histologic processing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9926=[""].join("\n");
var outline_f9_44_9926=null;
var title_f9_44_9927="Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging";
var content_f9_44_9927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Scott A Laurie, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9927/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9927/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/44/9927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic presents an overview of the spectrum of salivary gland tumors, including their clinical presentation, diagnosis, initial evaluation, and staging.",
"   </p>",
"   <p>",
"    Other relevant topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link\">",
"       \"Salivary gland tumors: Treatment of locoregional disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=see_link\">",
"       \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathology of head and neck neoplasms\", section on 'Salivary gland tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267160259\">",
"    <span class=\"h1\">",
"     SPECTRUM OF SALIVARY GLAND TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors constitute an uncommon, heterogeneous group of neoplasms that vary considerably in their anatomic site of origin, histology, and biologic behavior (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    ). Both benign and malignant salivary gland tumors are classified according to the 2005 World Health Organization system (",
"    <a class=\"graphic graphic_table graphicRef70453 \" href=\"UTD.htm?20/36/21069\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathology of head and neck neoplasms\", section on 'Salivary gland tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anatomically, the parotid gland is the most frequent site of salivary gland tumors, accounting for approximately 80 to 85 percent of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. About three-fourths of parotid lesions are benign and approximately 25 percent are malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less frequently, salivary gland tumors originate in the submandibular, sublingual, and minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast to tumors arising in the parotid, 40 to 45 percent of submandibular gland tumors, 70 to 90 percent of sublingual gland tumors, and 50 to 75 percent of minor salivary gland tumors are malignant.",
"   </p>",
"   <p>",
"    Histologically, the most common type of benign salivary gland tumor is the pleomorphic adenoma, which comprises about half of all salivary tumors. Other rarer benign salivary gland tumors include Warthin tumor, basal cell adenoma, and canalicular adenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathology of head and neck neoplasms\", section on 'Salivary gland tumors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The most common malignant salivary gland tumors include mucoepidermoid carcinoma and adenoid cystic carcinoma, which together comprise approximately one-half of all malignant salivary gland tumors. Salivary gland cancers can vary in their aggressiveness and their propensity to recur and metastasize. A histologic grading system has been proposed, in which salivary gland malignancies are classified as high-grade or low- to intermediate-grade based upon clinical behavior and outcomes (",
"    <a class=\"graphic graphic_table graphicRef64529 \" href=\"UTD.htm?29/62/30699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A higher tumor grade appears to correlate with more aggressive behavior in mucoepidermoid carcinoma and adenocarcinoma not otherwise specified, but there are conflicting data on the importance of grading according to histological pattern in adenoid cystic carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathology of head and neck neoplasms\", section on 'Salivary gland tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare but aggressive salivary gland tumors include primary small cell carcinomas, which account for about 1 to 2 percent of all salivary gland tumors and often have distant disease at presentation and salivary ductal carcinoma, a cancer of older men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link&amp;anchor=H18#H18\">",
"     \"Extrapulmonary small cell cancer\", section on 'Salivary gland ESCC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to primary tumors arising the salivary glands, other malignancies that arise in the head and neck region (eg, lymphoma, cutaneous squamous cell carcinoma, melanoma) can present as major salivary gland masses due to lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. These may account for up to 10 percent of major salivary gland masses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link&amp;anchor=H8#H8\">",
"     \"Classification of the hematopoietic neoplasms\", section on 'Lymphoid neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors are rare, representing only 6 to 8 percent of head and neck tumors; in the United States there are approximately 2000 to 2500 cases per year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There are substantial geographic variations in the incidence of salivary gland tumors and in the types of tumors in a given area.",
"   </p>",
"   <p>",
"    Although there is no one predominant known factor associated with the development of salivary gland cancer, a number of factors have been implicated as potential causes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation exposure has been associated with the development of both benign and malignant salivary gland tumors. This relationship was initially based upon data from atomic bomb survivors in Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/5\">",
"       5",
"      </a>",
"      ]. There also appears to be an increased risk in long-term cancer survivors who received radiation therapy as part of their treatment for Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/6\">",
"       6",
"      </a>",
"      ] and individuals who received radiation to the head and neck region for childhood cancers or benign conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Warthin tumor has a strong association with smoking, in contrast to other salivary gland tumors for which there is no clear relationship. Although this benign tumor has been historically associated with older men, the incidence in women has increased and parallels the increased smoking rates of women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1,9,10\">",
"       1,9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral infections may be associated with an increased risk of salivary gland cancers. Epidemiologic studies have reported an increased incidence of these tumors in individuals infected with HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Lymphoepithelial carcinoma is an undifferentiated carcinoma that accounts for less than 1 percent of salivary gland tumors; lymphoepithelial carcinoma has been strongly associated with Epstein Barr virus (EBV) in areas where EBV is endemic [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Environmental factors and industrial exposure to factors such as rubber manufacturing, hair dressers, beauty shops, and nickel compounds have been reported to be associated with the development of salivary gland tumors. [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/2,13,14\">",
"       2,13,14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of a salivary gland neoplasm depends upon its specific site of origin and the extent of involvement of adjacent organs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a tumor of a major salivary gland typically present with a painless mass or swelling of the parotid, submandibular, or sublingual gland. The presence of a parotid mass in combination with signs or symptoms indicative of facial nerve involvement (eg, facial nerve paralysis) is generally indicative of a malignant rather than a benign tumor.",
"     </li>",
"     <li>",
"      Minor salivary gland tumors arising within the oral cavity may present with a painless submucosal mass or mucosal ulceration in the palate, lips, or buccal mucosa, with an appearance similar to sialometaplasia (squamous metaplasia of salivary glands) or squamous cell carcinoma. Symptoms due to more advanced minor salivary gland tumors are a function of the location of the tumor and can include nasal obstruction, congestion, vision changes, or trismus when present in the nasal cavity or maxillary sinus. Minor salivary gland tumors involving the nasopharynx usually present at an advanced stage; invasion of the skull base, intracranial extension, or involvement of cranial nerves is common [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumors with a high malignant potential are more likely to spread to regional lymph nodes and result in a palpable mass (",
"    <a class=\"graphic graphic_table graphicRef64529 \" href=\"UTD.htm?29/62/30699\">",
"     table 2",
"    </a>",
"    ). Lymphatic drainage varies according to location of the salivary gland: for parotid malignancies, which constitute the majority of salivary gland tumors, the first site of lymphatic spread is the intraparotid lymph nodes, followed by level I and level II cervical nodes (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"UTD.htm?18/53/19285\">",
"     figure 2",
"    </a>",
"    ). Submandibular gland tumors spread to adjacent perivascular nodes and then to the cervical region. The sublingual gland drains to the submental and submandibular nodes, and the minor salivary glands within the oropharynx drain to the retropharyngeal nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7558?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of a neck mass\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distant metastases most frequently localize to the lung, followed by bone and liver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/16\">",
"     16",
"    </a>",
"    ]. Adenoid cystic carcinoma is associated with a high risk of distant metastases that can occur as late as 10 to 20 years after diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6966761\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of pathologic processes can cause a salivary gland mass or enlargement. In addition to benign and malignant tumors, the differential diagnosis of patients includes salivary cysts, cysts of the first branchial cleft, salivary gland stones, sarcoid, Sj&ouml;gren's syndrome, metastases from other tumors, lymphoepithelial cysts (particularly in an immunocompromised host), chronic sclerosing sialadenitis (K&uuml;ttner's tumor), and regional lymphadenopathy from infectious, inflammatory, or malignant diseases. Distinguishing among these possibilities may require a tissue diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=see_link\">",
"     \"Differential diagnosis of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients presenting with a facial nerve palsy, a high suspicion of malignant involvement of the parotid gland must be entertained in those with a history of skin cancer or melanoma of the scalp or face, as well as in those with a history of removal of skin lesion that was not sent for pathologic examination.",
"   </p>",
"   <p>",
"    A malignant parotid tumor must be distinguished from Bell&rsquo;s palsy. Patients with an apparent Bell&rsquo;s palsy require further evaluation if there are other neurologic abnormalities, features on physical examination that suggest a parotid tumor, or if there is no evidence of improvement within a reasonable time frame [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link&amp;anchor=H10#H10\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare causes of facial nerve paralysis that must be distinguished from a parotid tumor include sarcoid infiltration of the parotid gland (known as Heerfordt's syndrome) and intraparotid facial nerve schwannoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267160930\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598833401\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial history should evaluate the duration the mass has been present, the rapidity of its growth, and the presence of pain, numbness, or any subtle asymmetry of facial motion. In addition, the patient should be questioned for a history of previous skin cancers such as squamous cell carcinoma or melanoma of the scalp or facial region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7558?source=see_link\">",
"     \"Evaluation of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination should document the size of the mass, its mobility, fixation to overlying skin or to deep structures, any limitation in jaw opening, pharyngeal asymmetry or buccal involvement, pain with palpation, skin or scalp lesions suggestive of primary malignancy, and detailed facial nerve examination that details specific branch involvement if present. Examination of the neck should include assessment for cervical lymphadenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598833408\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of imaging studies in addition to physical exam in the evaluation of salivary gland tumors is to differentiate neoplastic from benign disease, define intra- versus extra-glandular location, assess local extension and invasion, and detect nodal and systemic metastases.",
"   </p>",
"   <p>",
"    The initial imaging evaluation varies in part based upon the location of the enlarged gland:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both computed tomography (CT) and magnetic resonance imaging (MRI) may be necessary to assess the extent of a salivary gland tumor, which may be greater than can be appreciated on physical examination. Such imaging is also useful to evaluate local, bony, and perineural invasion, and lymph node metastases, as well as to assess the parapharyngeal space for involvement from lesions in the parotid [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. MRI is suggested in evaluation of all sublingual gland tumors given the high risk for malignant disease. Temporal bone or mandibular destruction is best identified by CT, while MRI permits more detailed evaluation of soft tissue infiltration, perineural invasion, and intracranial extension [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, CT or MRI can provide anatomic details that are useful for surgical planning.",
"     </li>",
"     <li>",
"      Depending upon the location and size of a mass, ultrasound may also provide high quality resolution and tissue characterization while being timely and cost effective for imaging the parotid, submandibular, and sublingual glands [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. These glands are superficial structures and are readily amenable to high resolution ultrasound examination. In addition, ultrasound can facilitate fine needle aspiration (FNA) and core needle biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Ultrasound is not as useful as other modalities for planning surgical treatment.",
"     </li>",
"     <li>",
"      When a Warthin tumor is diagnosed, both parotid glands should be imaged since these tumors have a tendency for multifocality and bilaterality [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Synchronous bilateral malignancy in the parotid glands is rare in other histologic tumor types [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6966596\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tissue diagnosis is required to make the diagnosis of a salivary gland tumor and to determine whether such a tumor is benign or malignant.",
"   </p>",
"   <p>",
"    The tissue diagnosis should be obtained prior to definitive treatment whenever possible to avoid major surgery for a benign tumor or a lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/2\">",
"     2",
"    </a>",
"    ]. Options include fine aspiration (FNA) or ultrasound-guided core needle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Both techniques are safe, simple procedures that can help direct subsequent evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/29,31-34\">",
"     29,31-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link\">",
"     \"Salivary gland tumors: Treatment of locoregional disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the parotid, submandibular, and sublingual glands are staged according to the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) tumor node metastases (TNM) system (",
"    <a class=\"graphic graphic_table graphicRef61042 \" href=\"UTD.htm?34/52/35661\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/35\">",
"     35",
"    </a>",
"    ]. Tumors arising in minor salivary glands are staged according to their anatomic site of origin.",
"   </p>",
"   <p>",
"    Imaging studies (CT, MRI) that are obtained prior to diagnosis can provide important information for staging in those patients who are ultimately found to have a malignant tumor. Although not routine in the evaluation of all malignant salivary gland tumors, 18F-fluorodeoxyglucose positron emission tomography (FDG PET) has good diagnostic accuracy in the assessment of regional lymph nodes and distant metastases in patients with salivary gland malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be more accurate than PET alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9927/abstract/39\">",
"     39",
"    </a>",
"    ]. However, PET is not able to distinguish benign from malignant parotid tumors. CT may also useful to examine the chest to rule out lung metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salivary gland tumors comprise a rare, diverse group of benign and malignant histologies. Most salivary gland tumors are benign and occur in the parotid gland. Pleomorphic adenoma is the most common of these benign lesions. Tumors of the submandibular, sublingual, and minor salivary glands are more likely than parotid tumors to be malignant. (See",
"      <a class=\"local\" href=\"#H267160259\">",
"       'Spectrum of salivary gland tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with salivary gland tumors present with a painless mass or swelling. However, the differential diagnosis of a salivary gland mass includes a wide range of cystic and inflammatory disorders, as well as benign and malignant tumors (",
"      <a class=\"graphic graphic_table graphicRef70453 \" href=\"UTD.htm?20/36/21069\">",
"       table 1",
"      </a>",
"      ). Neurologic signs or symptoms, such as facial nerve paralysis, indicative of facial nerve involvement, are almost always indicative of a malignant tumor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6966761\">",
"       'Differential diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      A tissue diagnosis is required to establish a definitive diagnosis of a salivary gland tumor and to plan therapy. If anatomically feasible, a preoperative biopsy (either fine needle aspiration cytology or ultrasound guided core needle) can be performed to avoid operating on a nonsurgically-managed disease process and to aid in surgical planning. However, a preoperative histologic diagnosis is not always possible. (See",
"      <a class=\"local\" href=\"#H267160930\">",
"       'Initial assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6966596\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignancies of the parotid, submandibular, and sublingual glands are staged according to the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) tumor node metastases (TNM) system (",
"      <a class=\"graphic graphic_table graphicRef61042 \" href=\"UTD.htm?34/52/35661\">",
"       table 3",
"      </a>",
"      ). Tumors arising in minor salivary glands are staged according to their anatomic site of origin. Imaging studies using CT, MRI, and in some cases PET may provide important information about the extent of local invasion or dissemination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tumours of the Salivary Glands. In: Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D.  (Eds), World Health Organization, Lyon 2005. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/2\">",
"      Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010; 74:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/3\">",
"      Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/4\">",
"      O'Brien CJ, Malka VB, Mijailovic M. Evaluation of 242 consecutive parotidectomies performed for benign and malignant disease. Aust N Z J Surg 1993; 63:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/5\">",
"      Saku T, Hayashi Y, Takahara O, et al. Salivary gland tumors among atomic bomb survivors, 1950-1987. Cancer 1997; 79:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/6\">",
"      Boukheris H, Ron E, Dores GM, et al. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 2008; 113:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/7\">",
"      Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/8\">",
"      Boukheris H, Stovall M, Gilbert ES, et al. Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 2013; 85:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/9\">",
"      Pinkston JA, Cole P. Cigarette smoking and Warthin's tumor. Am J Epidemiol 1996; 144:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/10\">",
"      de Ru JA, Plantinga RF, Majoor MH, et al. Warthin's tumour and smoking. B-ENT 2005; 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/11\">",
"      Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/12\">",
"      Shebl FM, Bhatia K, Engels EA. Salivary gland and nasopharyngeal cancers in individuals with acquired immunodeficiency syndrome in United States. Int J Cancer 2010; 126:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/13\">",
"      Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997; 8:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/14\">",
"      Swanson GM, Burns PB. Cancers of the salivary gland: workplace risks among women and men. Ann Epidemiol 1997; 7:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/15\">",
"      Schramm VL Jr, Imola MJ. Management of nasopharyngeal salivary gland malignancy. Laryngoscope 2001; 111:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/16\">",
"      Licitra L, Grandi C, Prott FJ, et al. Major and minor salivary glands tumours. Crit Rev Oncol Hematol 2003; 45:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/17\">",
"      Quesnel AM, Lindsay RW, Hadlock TA. When the bell tolls on Bell's palsy: finding occult malignancy in acute-onset facial paralysis. Am J Otolaryngol 2010; 31:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/18\">",
"      Caughey RJ, May M, Schaitkin BM. Intraparotid facial nerve schwannoma: diagnosis and management. Otolaryngol Head Neck Surg 2004; 130:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/19\">",
"      Lee YY, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumours. Eur J Radiol 2008; 66:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/20\">",
"      Hisatomi M, Asaumi J, Yanagi Y, et al. Diagnostic value of dynamic contrast-enhanced MRI in the salivary gland tumors. Oral Oncol 2007; 43:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/21\">",
"      Koyuncu M, Se��en T, Akan H, et al. Comparison of computed tomography and magnetic resonance imaging in the diagnosis of parotid tumors. Otolaryngol Head Neck Surg 2003; 129:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/22\">",
"      Kotecha S, Bhatia P, Rout PG. Diagnostic ultrasound in the head and neck region. Dent Update 2008; 35:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/23\">",
"      Koischwitz D, Gritzmann N. Ultrasound of the neck. Radiol Clin North Am 2000; 38:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/24\">",
"      Bia��ek EJ, Jakubowski W, Karpi��ska G. Role of ultrasonography in diagnosis and differentiation of pleomorphic adenomas: work in progress. Arch Otolaryngol Head Neck Surg 2003; 129:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/25\">",
"      Feld R, Nazarian LN, Needleman L, et al. Clinical impact of sonographically guided biopsy of salivary gland masses and surrounding lymph nodes. Ear Nose Throat J 1999; 78:905, 908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/26\">",
"      Maiorano E, Lo Muzio L, Favia G, Piattelli A. Warthin's tumour: a study of 78 cases with emphasis on bilaterality, multifocality and association with other malignancies. Oral Oncol 2002; 38:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/27\">",
"      Hilton JM, Phillips JS, Hellquist HB, Premachandra DJ. Multifocal multi-site Warthin tumour. Eur Arch Otorhinolaryngol 2008; 265:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/28\">",
"      van Tongeren J, Creytens DH, Meulemans EV, et al. Synchronous bilateral epithelial-myoepithelial carcinoma of the parotid gland: case report and review of the literature. Eur Arch Otorhinolaryngol 2009; 266:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/29\">",
"      Christensen RK, Bj&oslash;rndal K, Godballe C, Krogdahl A. Value of fine-needle aspiration biopsy of salivary gland lesions. Head Neck 2010; 32:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/30\">",
"      Zb&auml;ren P, Gu&eacute;lat D, Loosli H, Stauffer E. Parotid tumors: fine-needle aspiration and/or frozen section. Otolaryngol Head Neck Surg 2008; 139:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/31\">",
"      Howlett DC, Menezes LJ, Lewis K, et al. Sonographically guided core biopsy of a parotid mass. AJR Am J Roentgenol 2007; 188:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/32\">",
"      Wan YL, Chan SC, Chen YL, et al. Ultrasonography-guided core-needle biopsy of parotid gland masses. AJNR Am J Neuroradiol 2004; 25:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/33\">",
"      Hughes JH, Volk EE, Wilbur DC, Cytopathology Resource Committee, College of American Pathologists. Pitfalls in salivary gland fine-needle aspiration cytology: lessons from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. Arch Pathol Lab Med 2005; 129:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/34\">",
"      Layfield LJ. Fine-needle aspiration in the diagnosis of head and neck lesions: a review and discussion of problems in differential diagnosis. Diagn Cytopathol 2007; 35:798.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/36\">",
"      Cermik TF, Mavi A, Acikgoz G, et al. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med 2007; 32:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/37\">",
"      Razfar A, Heron DE, Branstetter BF 4th, et al. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 2010; 120:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/38\">",
"      Kim MJ, Kim JS, Roh JL, et al. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. Ann Surg Oncol 2013; 20:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9927/abstract/39\">",
"      Adelstein DJ, Rodriguez CP. What is new in the management of salivary gland cancers? Curr Opin Oncol 2011; 23:249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3400 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9927=[""].join("\n");
var outline_f9_44_9927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267160259\">",
"      SPECTRUM OF SALIVARY GLAND TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6966761\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267160930\">",
"      INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598833401\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598833408\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6966596\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3400|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6449\" title=\"figure 1\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19285\" title=\"figure 2\">",
"      Lymph nodes head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21069\" title=\"table 1\">",
"      WHO class salivary gld tum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/62/30699\" title=\"table 2\">",
"      Grades salivary gland cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/52/35661\" title=\"table 3\">",
"      TNM stage salivary glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=related_link\">",
"      Differential diagnosis of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7558?source=related_link\">",
"      Evaluation of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=related_link\">",
"      Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9928="Evaluation of the patient with thumb pain";
var content_f9_44_9928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with thumb pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9928/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9928/contributors\">",
"     James Bray, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9928/contributors\">",
"     Sara Neal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9928/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9928/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/44/9928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14961508\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to the hand, wrist, and fingers, including the thumb, are common. According to the National Hospital Ambulatory Medical Care Survey for the year 2004, 11.3 percent of all visits to United States emergency departments involved such injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review how to perform the initial evaluation of patients with thumb pain, whether from injuries or other conditions. Finger and thumb anatomy and detailed discussions of specific injuries and conditions are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For finger and hand injuries: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=see_link\">",
"     \"Middle phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=see_link\">",
"     \"Proximal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link\">",
"     \"Digit dislocation reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25879?source=see_link\">",
"     \"Evaluation of the patient with hand pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"     \"Overview of metacarpal fractures\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For wrist injuries: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link\">",
"     \"Evaluation of the adult with acute wrist pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For other conditions: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27993?source=see_link\">",
"     \"Overview of hand infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961515\">",
"    <span class=\"h1\">",
"     FUNCTIONAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thumb is composed of two phalanges, not three as with other fingers. The distal and proximal phalanges articulate at the interphalangeal (IP) joint. The proximal phalanx articulates with the first metacarpal at the metacarpophalangeal (MCP) joint. The metacarpal is joined to the wrist at the carpometacarpal (CMC) joint, where it articulates with the trapezium. Finger and thumb anatomy are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link&amp;anchor=H8#H8\">",
"     \"Finger and thumb anatomy\", section on 'Thumb anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The thumb is spatially removed from the other digits, which makes it vulnerable to injury. This position and increased range of motion at the MCP and CMC joints allow the thumb greater movement than any other digit (",
"    <a class=\"graphic graphic_picture graphicRef53165 \" href=\"UTD.htm?41/14/42223\">",
"     picture 1",
"    </a>",
"    ). Nine muscles control the thumb&rsquo;s five primary movements (",
"    <a class=\"graphic graphic_table graphicRef77180 \" href=\"UTD.htm?17/1/17435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One important and unique action of the thumb is opposition with other digits. The thumb functions as a mobile, but stable &ldquo;post&rdquo; allowing the hand to grasp and pinch. Opposition requires the MCP and CMC joints to have some rotational capacity as well as flexion and extension.",
"   </p>",
"   <p>",
"    Unless noted, movements are defined from a starting position with the thumb, the fingers, and the palm in the same plane. The thumb rests at a 45 degree angle from the axis of the palm and fingers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961522\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the thumb begins with inspection for deformity and laceration or other signs of injury, including nail bed injury. Assess the alignment of the thumb column and joints. Obvious deformity raises the question of fracture or dislocation. Deformity and soft tissue injury may coexist and management priorities are determined by the severity of each. Deep skin lacerations may expose fractured bone or torn tendon, which should be addressed first. Nail bed injuries and simple lacerations are noted and treatment is provided after completion of the examination.",
"   </p>",
"   <p>",
"    Following inspection, palpate the distal and proximal phalanges, first metacarpal, interphalangeal (IP) joint, metacarpophalangeal (MCP) joint, and carpometacarpal (CMC) joint for tenderness and deformity. The differential diagnosis for pain at the joint without significant deformity includes subluxation and avulsion fracture of a muscle tendon unit and early onset degenerative disease. Subluxation may be associated with joint instability. An avulsion fracture is usually associated with some weakness or joint instability. Early degenerative disease of the MCP or CMC joints can present with warmth and erythema, in addition to joint pain and swelling, and most patients will describe a history of chronic or acute-on-chronic symptoms.",
"   </p>",
"   <p>",
"    Next, ask the patient to perform all thumb movements without resistance, noting any abnormalities (",
"    <a class=\"graphic graphic_picture graphicRef53165 \" href=\"UTD.htm?41/14/42223\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52102 \" href=\"UTD.htm?10/15/10492\">",
"     table 2",
"    </a>",
"    ). Then have the patient repeat these movements against active resistance, looking for weakness and instability by comparing the affected and unaffected sides (",
"    <a class=\"graphic graphic_picture graphicRef65820 graphicRef75553 graphicRef54507 graphicRef68303 graphicRef76098 \" href=\"UTD.htm?37/6/37994\">",
"     picture 2A-E",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The thumb tendons involved in extension can be palpated while the strength of the thumb is assessed. With the thumb extended, the tendons that form the &ldquo;anatomic snuffbox&rdquo; become prominent. The anatomic snuff box is formed by the abductor pollicis longus (APL) and the extensor pollicis brevis (EPB) tendons radially and the extensor pollicis longus (EPL) tendon on the ulnar side.",
"   </p>",
"   <p>",
"    Thumb weakness or inability to perform a specific movement indicates damage to the muscle tendon unit(s) responsible for that action, or less commonly nerve injury or intraarticular conditions, such as infection or arthritis. In cases of injury, clinicians can combine their knowledge of functional anatomy with examination findings to identify the damaged muscle tendon unit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link&amp;anchor=H8#H8\">",
"     \"Finger and thumb anatomy\", section on 'Thumb anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minor joint instability (10 to 15 percent increase in motion compared to the unaffected side) may reflect a simple sprain. Larger discrepancies in joint motion between affected and unaffected sides or the complete inability to perform a movement suggests tendon rupture. Examples are provided in the accompanying images (",
"    <a class=\"graphic graphic_picture graphicRef57173 \" href=\"UTD.htm?15/48/16130\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68890 \" href=\"UTD.htm?23/7/23665\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82259 \" href=\"UTD.htm?7/53/8017\">",
"     picture 5",
"    </a>",
"    ). The treatment of tendon rupture varies with the location. (See",
"    <a class=\"local\" href=\"#H14961615\">",
"     'Joint instability'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians should note that substantial but incomplete tendon ruptures may not manifest weakness or significant instability and can be missed during the physical examination. Conversely, significant tendon or bone injuries may reduce joint mobility in specific planes if tendon or bone fragments become lodged in places that block motion (eg, interposed within joints).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961529\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3045739\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs, including anteroposterior (AP) or posteroanterior (PA), lateral, and oblique views, are the initial studies obtained to assess thumb injuries. The lateral view should be a true lateral of the thumb, not a lateral of the hand. The AP of the thumb is best obtained with a Robert&rsquo;s view, wherein the forearm is placed in maximal pronation with the dorsum of the thumb lying directly on the x-ray cassette and the x-ray beam is shot at a 90 degree angle to the cassette (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69169 \" href=\"UTD.htm?23/45/24274\">",
"     image 1",
"    </a>",
"    ). If a scaphoid fracture is suspected, a complete wrist series should be obtained, including a scaphoid view. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link&amp;anchor=H6#H6\">",
"     \"Scaphoid fractures\", section on 'Plain radiographs'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    When evaluating an MCP joint that is not easily reducible or irreducible, a widened joint space on plain film raises concern for interposed soft tissue.",
"   </p>",
"   <p>",
"    A plain x-ray of the CMC joint can be difficult to interpret. A true lateral of this joint can be obtained by placing the forearm flat on the table with the hand in 20 degrees of pronation. The x-ray beam should be angled 10 degrees away from vertical (distal to proximal projection). &nbsp;",
"   </p>",
"   <p>",
"    Stress views of the MCP and CMC joints may be useful to evaluate joint stability. More than 30 degrees of MCP joint opening (or a relative increase of 15 degrees compared with the unaffected side) when an abduction stress is placed on the MCP joint raises suspicion for ligament rupture. Non-stress radiographs should be studied prior to obtaining any stress views to avoid converting a nondisplaced fracture into a displaced fracture. Children should not have stress views if there is any concern for growth plate injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961537\">",
"    <span class=\"h2\">",
"     Computed tomography (CT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT is useful for evaluating complex fractures at the base of the thumb, when plain radiographs reveal the presence of such injuries. CT may provide additional information about stability of some fractures, such as Rolando and Bennett fractures. (See",
"    <a class=\"local\" href=\"#H14961608\">",
"     'Fracture of the proximal phalanx'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17828?source=see_link&amp;anchor=H8#H8\">",
"     \"First (thumb) metacarpal fractures\", section on 'Intraarticular fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11764965\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of small ultrasound transducers with frequencies as high as 15 MHz has substantially improved the imaging of thumb injuries, and ultrasound is commonly used in Europe for this purpose. For both the MCP and CMC joint, ultrasound can accurately define the degree of subluxation, degenerative change, and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, direct visualization with ultrasound makes it easier to inject these smaller joints. Dynamic imaging in particular plays an important role in evaluating the extent of partial tendon tears and can also confirm the diagnosis of entities, such as DeQuervain&rsquo;s tenosynovitis. Fractures, bone spurring, and features of rheumatoid arthritis all have a characteristic appearance on ultrasound, while entities, such as trigger finger and ulnar collateral ligament injury (ie, gamekeeper&rsquo;s thumb), may also be diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15967240\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI may be useful for evaluating soft tissue injuries if the diagnosis remains unclear following clinical evaluation and imaging with plain radiographs and ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961544\">",
"    <span class=\"h1\">",
"     SOFT TISSUE INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many thumb injuries involve lacerations. A simple laceration can be repaired once an examination is completed. Major skin and soft tissue wounds that extend to fractured bone, lacerated tendons, an open tendon sheath, or into a joint capsule must be managed immediately, including referral to a hand surgeon, as operative exploration is often necessary. Other indications for referral include large, grossly contaminated wounds. These may require tetanus prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link&amp;anchor=H7#H7\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\", section on 'Immunization for patients with injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Damage to skin or soft tissue that is deep but does not appear to extend to bone, joint, or tendon requires careful examination under sterile conditions to ensure there is no such involvement. Local anaesthesia is needed to perform the examination properly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H11#H11\">",
"     \"Peripheral nerve block: Techniques\", section on 'Upper extremity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After copious irrigation with a sterile solution (eg, isotonic saline), perform a careful, systematic inspection looking for any evidence of bone, tendon or joint capsule injury. A laceration that is not grossly contaminated and reveals intact bone can be treated with irrigation and simple soft tissue and skin repair. &nbsp;",
"   </p>",
"   <p>",
"    Possible joint capsule injury can be confirmed by injection with colored fluid. One approach is to mix sterile isotonic saline with a few drops of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    and inject the liquid into the joint capsule away from the laceration site. Approximately one or two mL of fluid should be sufficient. Fluorescein stained fluid will not leak from the joint if the capsule is intact.",
"   </p>",
"   <p>",
"    Many thumb injuries are accompanied by a subungual hematoma. These can be quite painful, but most are easily treated with trephination and drainage; removal of the nail is often",
"    <strong>",
"     not",
"    </strong>",
"    necessary. More extensive nail injuries can involve an open tuft (distal phalanx) fracture and nail avulsions. Partial or complete nail avulsions are usually associated with extensive nail bed injury, which must be repaired. The evaluation and management of subungual hematoma and related injuries is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link\">",
"     \"Subungual hematoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4472?source=see_link\">",
"     \"Management of fingertip injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961558\">",
"    <span class=\"h1\">",
"     DEFORMITY: DISLOCATION AND FRACTURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3188787\">",
"    <span class=\"h2\">",
"     General approach and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deformity of the thumb raises concern for fracture or dislocation. Fracture can occur in the distal or proximal phalanx, metacarpal, or trapezium, where the metacarpal articulates with the wrist. We recommend obtaining x-rays for any gross deformity. Imaging may be unnecessary for bony tenderness without joint instability or gross deformity, although it is reasonable to obtain in the setting of high impact trauma. (See",
"    <a class=\"local\" href=\"#H14961529\">",
"     'Diagnostic Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The reduction of digit dislocations and adjunct procedures, such as digital blocks and sedation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link\">",
"     \"Digit dislocation reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H11#H11\">",
"     \"Peripheral nerve block: Techniques\", section on 'Upper extremity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961565\">",
"    <span class=\"h2\">",
"     Deformity at the CMC joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;An isolated dislocation of the CMC joint without an associated fracture is rare. The mechanism usually involves forced adduction of a flexed thumb or a direct axial load [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/3\">",
"     3",
"    </a>",
"    ]. Most often a crush injury (eg, thumb is stepped on or caught between two pieces of equipment), rather than a direct blow, is involved. Symptoms are pain and swelling at the base of the thumb. Multidirectional instability confirms the diagnosis. If a fracture or dislocation is suspected (ie, deformity, instability or focal tenderness following trauma is present), obtain plain radiographs. (See",
"    <a class=\"local\" href=\"#H14961529\">",
"     'Diagnostic Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    By the time patients present for medical evaluation, most dislocations of the CMC joint have completely or partially reduced and diagnosis is made of a fracture or subluxation, or frequently both. Common fractures at the CMC joint involve the base of the metacarpal and can be stable (eg, Rolando fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67033 \" href=\"UTD.htm?42/54/43886\">",
"     image 2",
"    </a>",
"    )) or unstable (eg, Bennett fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72289 \" href=\"UTD.htm?17/30/17888\">",
"     image 3",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17828?source=see_link\">",
"     \"First (thumb) metacarpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractures of the scaphoid are common, and should be considered in the differential diagnosis of patients with pain just proximal to the base of the thumb, particularly if trauma to the thumb or hand was sustained (eg, fall onto an outstretched hand). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    .) Fractures of the trapezium (carpal articulation of the thumb) are uncommon. The mechanism typically involves a fall onto a radially deviated closed fist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36915?source=see_link\">",
"     \"Trapezium fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractures involving any of the thumb joints can lead to arthritic changes. Therefore, CMC joint fracture or dislocation warrants referral to a hand specialist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/4\">",
"     4",
"    </a>",
"    ]. Depending upon the extent of injury, these fractures may be treated with closed reduction and percutaneous pinning or open reduction and internal fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961580\">",
"    <span class=\"h2\">",
"     Deformity at the MCP joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCP joint dislocations are usually due to a hyperextension injury. Dislocations are classified as either &ldquo;simple&rdquo; or &ldquo;complex&rdquo;. Simple dislocations present with the proximal phalanx at an angle to the axis of the metacarpal; complex dislocations occur when there is overlap of the proximal phalanx and the metacarpal (the axes of the two bones are parallel). Simple dislocations can be managed by closed reduction with adequate anesthesia while complex dislocations require operative intervention.",
"   </p>",
"   <p>",
"    Most dislocations of the MCP joint are dorsal. In other words, the proximal phalanx becomes lodged on dorsoradial surface of the metacarpal. Many dorsal dislocations present with the phalanx angled 60 to 90 degrees to the metacarpal. The articular surfaces remain in contact. Closed reduction should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link&amp;anchor=H19#H19\">",
"     \"Digit dislocation reduction\", section on 'Simple metacarpophalangeal or metatarsophalangeal dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally the MCP joint dislocates in a volar direction. The force required for volar dislocations is greater and often causes significant damage to the joint capsule. Operative treatment is generally required but an initial attempt at reduction is reasonable.",
"   </p>",
"   <p>",
"    With complex dislocations, the volar plate becomes interposed in the joint space. The appearance can be similar to a simple dislocation, but often there is less angulation. Often the proximal phalanx lies parallel to the metacarpal. The presence of soft tissue in the joint space complicates closed reduction, often making it impossible. Closed reductions may be attempted but generally they are best performed in the operating room by a hand surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961594\">",
"    <span class=\"h2\">",
"     Deformity at the IP joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;IP joint dislocations are not common. The usual mechanism involves a hyperextension force exerted at the joint. Although frequently associated with a ligament or volar plate injury, IP dislocations are amenable to closed reduction most of the time. Sideline reductions without anesthesia can be performed. Irreducible IP joint dislocations likely involve interposed tissue and require referral for open reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link&amp;anchor=H16#H16\">",
"     \"Digit dislocation reduction\", section on 'Interphalangeal dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961608\">",
"    <span class=\"h2\">",
"     Fracture of the proximal phalanx",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal phalanx fractures usually result from a direct blow. The fracture can be transverse, oblique, or spiral. Angulation and rotation is common and most fractures are unstable. If fracture is suspected, x-rays must be obtained and should include a true lateral and oblique view of the thumb. Some stable transverse fractures may be amenable to conservative management, but all spiral and oblique fractures are inherently unstable. Proximal phalanx fractures should generally be referred to a hand surgeon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=see_link\">",
"     \"Proximal phalanx fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2678110\">",
"    <span class=\"h2\">",
"     Fracture of distal phalanx (tuft fracture)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal phalanx fractures (ie, tuft fractures) usually result from a crush injury, but can also occur from an axial load. Fractures can be longitudinal, transverse, or comminuted (&ldquo;crushed eggshell&rdquo; appearance), and significant soft tissue and nail bed injuries may accompany them. These fractures are usually stable. If angulation is minimal and the soft tissue is intact, treatment with a protective splint that extends to the proximal phalanx and prevents motion at the IP joint is generally adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/7\">",
"     7",
"    </a>",
"    ]. Three to four weeks of splinting is generally sufficient, but longer treatment may be helpful if pain or tenderness of the tuft persists. Most tuft fractures, even those with extensive comminution, heal in two to four weeks.",
"   </p>",
"   <p>",
"    Soft tissue injury can be significant, sometimes involving nail avulsion and loss of fingertip pulp. We suggest obtaining hand surgery consultation for grossly contaminated injuries involving a fracture, irreducible or unstable fractures, transverse fractures of the distal phalanx with obvious angulation, or injuries associated with substantial soft tissue loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961615\">",
"    <span class=\"h1\">",
"     JOINT INSTABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor joint instability (eg, 10 to 15 percent increase in motion compared to the unaffected side) may reflect a simple sprain. This can be treated with protective splinting, rest, and follow up. Improvement should be noticeable within a few days. If not, we suggest further evaluation with diagnostic imaging. Greater joint instability suggests a more severe ligamentous injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961623\">",
"    <span class=\"h2\">",
"     MCP joint instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collateral ligaments stabilize the MCP joint against varus and valgus stress. However, such stress can injure the ulnar collateral ligament (UCL) or, less commonly, the radial collateral ligament (RCL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3188988\">",
"    <span class=\"h3\">",
"     Ulnar collateral ligament injury (skier&rsquo;s thumb)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the thumb is used to grasp a cylindrical object, such as a ski pole, baseball bat, or hammer, the UCL, which lies on the side of the thumb next to the index finger, is vulnerable to valgus stress. The mechanism for UCL sprain or rupture (often called &ldquo;skier&rsquo;s thumb&rdquo;) involves forceful abduction and hyperextension at the MCP joint, as might occur when a downhill skier falls and their thumb is thrust against a planted ski pole.",
"   </p>",
"   <p>",
"    The patient usually complains of pain at the ulnar aspect of the MCP joint and instability or weakness; examination reveals instability when valgus stress is applied to the MCP joint. UCL injuries may involve Stener lesions, in which the torn proximal end of the ligament becomes folded and trapped outside the aponeurosis, thereby preventing healing. Due to the importance of the UCL for thumb stability when grasping and the possibility of a Stener lesion, which can be difficult to diagnose clinically, referral to a hand surgeon is prudent when UCL injury is suspected. UCL injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=see_link\">",
"     \"Ulnar collateral ligament injury (gamekeeper's or skier's thumb)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3188995\">",
"    <span class=\"h3\">",
"     Radial collateral ligament injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radial collateral ligament (RCL) lies on the radial side of the thumb, farthest from the fingers. RCL injury occurs less often than injuries of the ulnar collateral ligament, but should be ruled out when thumb trauma occurs.",
"   </p>",
"   <p>",
"    An RCL tear or sprain causes tenderness over the MCP joint on the radial side of the thumb and instability with varus stress. Clinicians can test for MCP instability by placing their fingers on the ulnar side of the patient&rsquo;s thumb and their thumb on the radial side of the patient&rsquo;s thumb at its tip, and then applying a varus force across the joint. It is important to compare findings to the contralateral side as some patients have substantial joint flexibility at baseline. Pain without significant instability may reflect a simple sprain. Significant joint laxity, as demonstrated by a 15 degree difference in motion compared to the contralateral side, indicates a partial or complete ligament tear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike the ulnar side of the thumb, the radial side does not contain soft tissue structures that can lodge within the joint. If there is minimal instability and the joint functions normally, treatment with splinting for two to four weeks should be sufficient. Significant instability or joint dysfunction requires evaluation by a hand surgeon, as complete tears often require operative treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961637\">",
"    <span class=\"h2\">",
"     IP joint instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mallet thumb is a disruption of the terminal insertion of the extensor tendon onto the distal phalanx, and is the most common cause of IP joint instability. Mallet injuries occur less often in the thumb than the other fingers and differ from them in three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extensor pollicis longus (EPL) tendon is thicker at the distal end than the extensor tendons of the finger (extensor digitorum communis or EDC).",
"     </li>",
"     <li>",
"      The thumb IP joint has a greater range of motion than fingers&rsquo; distal interphalangeal joints (DIP).",
"     </li>",
"     <li>",
"      Greater forces are needed to rupture the EPL than the EDC so the mechanism of injury generally involves more than just an axial load.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early surgical repair of a mallet thumb is often needed because splinting the IP joint in extension with the thumb abducted (for protection) prevents athletes or heavy laborers from returning to activity. Conservative management consists of continuous splinting in extension for six weeks followed by night splinting for an additional six to eight weeks. If nonoperative treatment fails, refer the patient for operative management [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9928/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest obtaining x-rays in patients with IP joint instability to look for bony avulsion of the distal extensor tendon. The presence of a large fragment warrants referral to a hand specialist, as operative repair may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961672\">",
"    <span class=\"h1\">",
"     NONTRAUMATIC THUMB PAIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961630\">",
"    <span class=\"h2\">",
"     Stenosing flexor tenosynovitis (Trigger thumb)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigger thumb develops when the flexor tendon sheath thickens, creating a physical block to normal tendon movement via the pulley system. Symptoms include pain and tenderness at the base of the thumb on the palmar side or at the IP joint. The patient may note a catching sensation when extending the thumb. After the thumb is flexed, it may &ldquo;stick&rdquo; requiring the patient to use their opposite hand to force the thumb back into extension. On examination, clinicians may note a palpable nodule along the tendon sheath on the palmar side. Trigger finger is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=see_link\">",
"     \"Trigger finger (stenosing flexor tenosynovitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961658\">",
"    <span class=\"h2\">",
"     De Quervain&rsquo;s tenosynovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;De Quervain&rsquo;s tenosynovitis is an inflammation of the abductor pollicis longus (APL) and extensor pollicis brevis (EPB) tendons. It presents as pain and sometimes swelling at the radial styloid, extending toward the base of the thumb. Pain is aggravated by activities requiring repetitive grasping with the hand in ulnar deviation. These activities include golf, racket sports, and fly fishing. The Finkelstein&rsquo;s test (ulnar deviation of the wrist with the thumb grasped in the palm by the fingers) is often used to help make the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef58422 \" href=\"UTD.htm?22/14/22752\">",
"     picture 6",
"    </a>",
"    ). Symptoms of short (weeks) duration may improve with immobilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27270?source=see_link\">",
"     \"de Quervain's tenosynovitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14961665\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint pain at the MP or CMC joints unrelated to trauma raises concern for arthritis. This is particularly true if pain has been present for several months or longer. Both osteoarthritis and rheumatoid arthritis can affect the CMC joint.",
"   </p>",
"   <p>",
"    Osteoarthritis is a common cause of pain at the base of the thumb (CMC joint). Symptoms often include diffuse pain that is aggravated by sustained grasping or pinching (eg, sewing), or by forceful use of the thumb, such as turning a key. There may be a sensation of thumb weakness or of the joint &ldquo;slipping.&rdquo;",
"   </p>",
"   <p>",
"    The metacarpal may enlarge at its base, creating a mild deformity. There is typically no local warmth at the joint, but it is tender to palpation along the volar side. Applying an axial load on the metacarpal with slight rotation (the &ldquo;grind test&rdquo;) is painful. Crepitation may also be noted. Strength testing frequently reveals loss of pincer strength. Typically, characteristic changes are evident on plain radiographs. The evaluation and treatment of osteoarthritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rheumatoid arthritis (RA) primarily affects the thumb at the MP and CMC joints. The first symptoms are usually joint pain and stiffness. Pain initially is from synovial inflammation that precedes cartilage or bone destruction. As synovitis progresses, the synovium thickens and small joint effusions occur, increasing thumb stiffness and impairing function. Ultimately, tendon laxity and joint deformity develop.",
"   </p>",
"   <p>",
"    RA of the MP joint can lead to a Boutonniere deformity, while advanced disease at the CMC joint can lead to a swan neck deformity. Subluxation of the EPL into a volar and ulnar position creates the Boutonniere deformity, defined as a flexed MP joint combined with a hyperextended IP joint. The swan neck deformity involves MP joint hyperextension combined with IP joint flexion and metacarpal adduction.",
"   </p>",
"   <p>",
"    Rheumatoid arthritis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14431441\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and paresthesias along the median nerve distribution from carpal tunnel syndrome can be referred to the thumb along its palmar aspect. Carpal tunnel syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3045778\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thumb pain is a common complaint. The functional anatomy and examination of the thumb are described in the text. The examination should include assessment of all thumb movements and joint stability. (See",
"      <a class=\"local\" href=\"#H14961515\">",
"       'Functional anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14961522\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs, including anteroposterior or posteroanterior, lateral, and oblique views, are the initial studies obtained to assess thumb injuries. Ultrasound can be useful for dynamic assessment of ligament injuries or imaging of other soft tissue pathology. Computed tomography may be needed to evaluate complex fractures. (See",
"      <a class=\"local\" href=\"#H14961529\">",
"       'Diagnostic Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thumb trauma often results in soft tissue injury. A simple laceration can be repaired once an examination is completed. Major skin and soft tissue wounds that extend to a fractured bone, lacerated tendons, or an open tendon sheath or joint capsule must be managed immediately, including referral to a hand surgeon. (See",
"      <a class=\"local\" href=\"#H14961544\">",
"       'Soft tissue injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obvious deformity of the thumb following trauma raises concern for fracture or dislocation. Fractures of either phalanx and dislocations of the metacarpophalangeal joint are most common. (See",
"      <a class=\"local\" href=\"#H14961558\">",
"       'Deformity: dislocation and fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Joint instability following thumb trauma suggests a ligamentous injury. Tears of the ulnar collateral ligament and mallet thumb are most common. (See",
"      <a class=\"local\" href=\"#H14961615\">",
"       'Joint instability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontraumatic thumb pain usually represents a chronic or acute-on-chronic condition. Diagnoses to consider include stenosing flexor tenosynovitis (Trigger thumb), De Quervain&rsquo;s tenosynovitis, arthritis, and carpal tunnel syndrome. Important elements of each diagnosis are described in the text, but more complete discussions are found separately. (See",
"      <a class=\"local\" href=\"#H14961672\">",
"       'Nontraumatic thumb pain'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9928/abstract/1\">",
"      McCaig LF, Nawar EW. National Hospital Ambulatory Medical Care Survey: 2004 emergency department summary. Adv Data 2006; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9928/abstract/2\">",
"      Bodor M, Fullerton B. Ultrasonography of the hand, wrist, and elbow. Phys Med Rehabil Clin N Am 2010; 21:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9928/abstract/3\">",
"      Hong E. Hand injuries in sports medicine. Prim Care 2005; 32:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9928/abstract/4\">",
"      Peterson JJ, Bancroft LW. Injuries of the fingers and thumb in the athlete. Clin Sports Med 2006; 25:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9928/abstract/5\">",
"      Rettig AC. Athletic injuries of the wrist and hand: part II: overuse injuries of the wrist and traumatic injuries to the hand. Am J Sports Med 2004; 32:262.",
"     </a>",
"    </li>",
"    <li>",
"     DeLee, JC, Drez, D. Orthopaedic Sports Medicine: Principles and Practice, 2, WB Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     Eiff, MP, Hatch, RL, Calmbach, WL. Fracture Management for Primary Care, WB Saunders , Philadelphia 2003.",
"    </li>",
"    <li>",
"     Merrell, Greg, and Slade, Joseph F. Dislocations and ligament injuries in the digits. In: Green's Operative Hand Surgery, 6th ed, Wolfe, SW, Hotchkiss, RN, Pederson, WC, Kozin, SH. (Eds), Elsevier, Philadelphia 2011. Vol 1, p.323.",
"    </li>",
"    <li>",
"     Rockwood, CA, Green, DP, Bucholz, RW. Rockwood and Green's Fractures in Adults: Part 1., 3rd, JP Lippincott, New York 1991.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 249 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9928=[""].join("\n");
var outline_f9_44_9928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3045778\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961508\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961515\">",
"      FUNCTIONAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961522\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961529\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3045739\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961537\">",
"      Computed tomography (CT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11764965\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15967240\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961544\">",
"      SOFT TISSUE INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961558\">",
"      DEFORMITY: DISLOCATION AND FRACTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3188787\">",
"      General approach and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961565\">",
"      Deformity at the CMC joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961580\">",
"      Deformity at the MCP joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961594\">",
"      Deformity at the IP joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961608\">",
"      Fracture of the proximal phalanx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2678110\">",
"      Fracture of distal phalanx (tuft fracture)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961615\">",
"      JOINT INSTABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961623\">",
"      MCP joint instability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3188988\">",
"      - Ulnar collateral ligament injury (skier&rsquo;s thumb)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3188995\">",
"      - Radial collateral ligament injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961637\">",
"      IP joint instability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14961672\">",
"      NONTRAUMATIC THUMB PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961630\">",
"      Stenosing flexor tenosynovitis (Trigger thumb)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961658\">",
"      De Quervain&rsquo;s tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14961665\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14431441\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3045778\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/249\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/249|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/45/24274\" title=\"diagnostic image 1\">",
"      True AP x-ray of the thumb (Roberts view)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/54/43886\" title=\"diagnostic image 2\">",
"      Rolando fracture of thumb metacarpal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/30/17888\" title=\"diagnostic image 3\">",
"      Fracture of thumb metacarpal base Bennetts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/249|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42223\" title=\"picture 1\">",
"      Thumb movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/26/36257\" title=\"picture 2A\">",
"      Resisted thumb adduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/1/19472\" title=\"picture 2B\">",
"      Resisted thumb abduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/18/39203\" title=\"picture 2C\">",
"      Resisted thumb extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/38/20066\" title=\"picture 2D\">",
"      Resisted thumb flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/59/27569\" title=\"picture 2E\">",
"      Resisted thumb opposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/48/16130\" title=\"picture 3\">",
"      Stable UCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/7/23665\" title=\"picture 4\">",
"      Unstable UCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/53/8017\" title=\"picture 5\">",
"      Complete UCL tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/14/22752\" title=\"picture 6\">",
"      Finkelstein test deQuervains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/249|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/1/17435\" title=\"table 1\">",
"      Muscles of thumb movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/15/10492\" title=\"table 2\">",
"      Examination of thumb",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=related_link\">",
"      Digit dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=related_link\">",
"      Evaluation of the adult with acute wrist pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25879?source=related_link\">",
"      Evaluation of the patient with hand pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17828?source=related_link\">",
"      First (thumb) metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4472?source=related_link\">",
"      Management of fingertip injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=related_link\">",
"      Middle phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27993?source=related_link\">",
"      Overview of hand infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=related_link\">",
"      Overview of metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=related_link\">",
"      Proximal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=related_link\">",
"      Subungual hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36915?source=related_link\">",
"      Trapezium fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=related_link\">",
"      Trigger finger (stenosing flexor tenosynovitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=related_link\">",
"      Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27270?source=related_link\">",
"      de Quervain's tenosynovitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9929="Nonarteritic ischemic optic neuropathy: Prognosis and treatment";
var content_f9_44_9929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonarteritic ischemic optic neuropathy: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Madhura Tamhankar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Nicholas J Volpe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9929/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/44/9929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic optic neuropathy is the most common acute optic nerve disorder in patients over age 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/1\">",
"     1",
"    </a>",
"    ]. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar), and as arteritic versus nonarteritic. Anterior involvement is usual with both arteritic and nonarteritic ischemic optic neuropathy.",
"   </p>",
"   <p>",
"    Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling.",
"   </p>",
"   <p>",
"    This topic will discuss the prognosis and treatment of NAION. The epidemiology, pathogenesis, etiologies, clinical features, and diagnosis of NAION are discussed separately. Other forms of ischemic optic neuropathy and other optic neuropathies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"     \"Optic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Visual prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the onset of NAION, vision may deteriorate in some patients over the first few days or weeks. In the Ischemic Optic Neuropathy Decompression Trial (IONDT), 207 patients with an initial visual acuity of",
"    <span class=\"nowrap\">",
"     20/64",
"    </span>",
"    were reevaluated within 30 days; 29 percent of these patients had progressed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/2\">",
"     2",
"    </a>",
"    ]. Others report that among patients with a broad spectrum of visual loss at presentation, 5 to 11 percent of patients have significant visual acuity worsening over this time period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After this initial period of potential visual decline, most patients stabilize or improve; 25 to 40 percent of patients can have significant improvement in visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Continued progression is unusual; progressive worsening should prompt investigation into alternative causes of vision loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .) In the IONDT, 43 percent of patients with an initial baseline visual acuity of",
"    <span class=\"nowrap\">",
"     20/64",
"    </span>",
"    or worse had significantly improved vision (three lines or more) at six months; 31 percent had sustained this degree of recovery at 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. No specific demographic factor or comorbidity (eg, age, gender, diabetes, hypertension) has been associated with visual outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disc edema typically resolves over two to three months, and is followed by optic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/8\">",
"     8",
"    </a>",
"    ]. At six months, the disc appears pale, usually in a diffuse, but sometimes sectoral, pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast to patients with giant cell arteritis, patients with NAION do not develop clinically evident optic nerve cupping [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of NAION in the affected eye is not common; studies report a less than 6 percent same-eye recurrence rate at two years, which may increase to as high as 7.6 percent at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of recurrence in the fellow eye was traditionally believed to be quite high, but prospective studies have found it to be lower than previously thought, with an estimated five-year cumulative incidence of 12 to 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In the IONDT, 418 patients with NAION were prospectively evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/15\">",
"     15",
"    </a>",
"    ]. At baseline, 21 percent had a history or clinical evidence of NAION in the fellow eye. After a median follow-up of five years, 15 percent of patients developed NAION in the other eye, with a median interval between events of 1.2 years (range 16 days to 6 years).",
"   </p>",
"   <p>",
"    Diabetes and worse baseline visual acuity in the affected eye have been identified as risk factors for recurrence, but older age, gender, hypertension, anemia, migraine, and smoking have not [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Patients with diabetes are also more likely to have second eye involvement at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/17\">",
"     17",
"    </a>",
"    ]. Younger patients may be at greater risk of recurrence. In a retrospective study of 164 patients less than 50 years in age, 5 percent had evidence of fellow eye involvement at baseline, 5 percent had simultaneous bilateral involvement, and 32 percent had sequential involvement with a median time between events of one year (range one week to 14 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many series, the severity of the initial event appears to predict the severity of the subsequent event [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/1,2,15,18\">",
"     1,2,15,18",
"    </a>",
"    ], however one-third of patients will have a greater than six-line difference in visual acuities between affected eyes making an initial mild event not entirely reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mortality and other vascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NAION do not appear to have a higher mortality or risk for stroke or cardiovascular disease than would otherwise be expected on the basis of their underlying comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known effective therapy for NAION to ameliorate the degree of visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/1,22,23\">",
"     1,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    therapy does not appear to influence visual outcomes of acute NAION. In a retrospective case-control study, 23 patients treated with aspirin before and during the course of NAION were compared to 55 patients with NAION who did not use aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/24\">",
"     24",
"    </a>",
"    ]. Visual outcomes (visual acuity and mean deviation on automated perimetry) were similar in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop NAION in the setting of severe hypotension may benefit from prompt efforts to reverse hypotension, according to uncontrolled observations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. If this has occurred in the setting of acute blood loss, blood tranfusion is advised.",
"   </p>",
"   <p>",
"    Patients with acutely elevated blood pressure should have their blood pressure lowered incrementally rather than abruptly, as this has been described as precipitating NAION in at least one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting the use of corticosteroid therapy in NAION is limited and this is not a recommended treatment for NAION. Corticosteroids are sometimes used in NAION, particularly when there is concern that giant cell arteritis has not been excluded, but also in cases of severe bilateral vision loss as can occur in the perioperative or dialysis setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H12#H12\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Perioperative ION'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some anecdotal reports suggest that corticosteroids may have some benefit in NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. One retrospective study examined outcomes in 613 patients with NAION, 312 of whom were treated with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/32\">",
"     32",
"    </a>",
"    ]. Treated patients were somewhat younger and less likely to have hypertension or diabetes. After a median followup of 3.8 years, a benefit for treatment was observed in the subgroup of 70 eyes with initial acuity of",
"    <span class=\"nowrap\">",
"     20/70",
"    </span>",
"    or worse, who were treated within two weeks of onset; 70 percent improved two or more lines compared with 41 percent in the untreated group. In this subgroup, visual field defects were also more likely to improve in the treated compared with the untreated group (40 versus 25 percent). While the author concluded that early (within two weeks) treatment with corticosteroids leads to improvement in both visual acuity and visual fields, the findings from this nonblinded, nonrandomized study require prospective validation in a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Optic Nerve Sheath Decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In optic nerve sheath decompression surgery (ONDS), two or more slits or a window in the optic nerve sheath are created. This allows cerebrospinal fluid to escape, purportedly reducing the pressure surrounding the optic nerve. Compression of the optic nerve sheath is possibly pathogenic in NAION, and in initial reports, this appeared to be a promising strategy in reducing optic nerve damage in NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of ONDS was evaluated in a single masked, multicenter, randomized clinical trial, the Ischemic Optic Neuropathy Decompression Trial (IONDT) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/2\">",
"     2",
"    </a>",
"    ]. Recruitment was halted early, two years after the study was initiated.",
"   </p>",
"   <p>",
"    The initial report of the IONDT described six-month outcomes in 244 patients with NAION with age &gt;50 years and a baseline visual acuity worse than",
"    <span class=\"nowrap\">",
"     20/64",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/7\">",
"     7",
"    </a>",
"    ]. Improved visual acuity by at least three lines occurred in 33 percent of the surgical group compared to 43 percent of controls. Visual acuity worsened by at least three lines in 24 percent of the surgical group compared with 12 percent of controls. These results indicate no benefit and possible harm from surgery. At 24 months, 31 and 29 percent of the surgery group and controls had improved vision, while 20 percent in the surgery and 22 percent in the control group had worsened visual acuity compared with baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/6\">",
"     6",
"    </a>",
"    ]. Adverse effects of surgery included pain, diplopia, and central retinal artery occlusion.",
"   </p>",
"   <p>",
"    The conclusions of IONDT were that ONDS appears to be of no value to most patients with NAION and could potentially cause further visual deterioration. An unexpectedly high rate of spontaneous improvement in visual acuity was observed in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]; this was higher than previously reported. ONDS was associated with a lower rate of improvement; at 3, 6, and 12 months of follow-up, patients receiving surgery had a greater risk of losing three or more lines of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Optic neurotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This investigational surgical procedure relaxes the scleral ring surrounding the prelaminar and laminar regions of the optic nerve head, with the goal of reducing constriction and preventing necrosis of underperfused nerve fibers. In one study, seven selected patients with severe vision loss",
"    <span class=\"nowrap\">",
"     (&lt;20/800)",
"    </span>",
"    from NAION underwent transvitreal nasal radial optic neurotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/34\">",
"     34",
"    </a>",
"    ]. Six patients had visual improvement. The mean preoperative visual acuity was",
"    <span class=\"nowrap\">",
"     20/2400.",
"    </span>",
"    After a mean 13 weeks following surgery, the mean visual acuity was",
"    <span class=\"nowrap\">",
"     20/250,",
"    </span>",
"    with an average of 10 lines of improvement. In the two patients with sufficient visual acuity for preoperative perimetry, visual fields also significantly improved after surgery.",
"   </p>",
"   <p>",
"    While this report appears somewhat promising, there was no control group for comparison. Others are skeptical regarding the potential biomechanical effect of this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/35\">",
"     35",
"    </a>",
"    ]. Moreover, while serious complications were not reported in this series, surgical manipulation of the optic nerve head has the potential to further damage nerve fibers and blood vessels, potentially causing devastating loss of vision [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vitrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case series of 16 patients with NAION had findings on optical coherence tomography and ultrasound that were consistent with partial posterior vitreous detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/37\">",
"     37",
"    </a>",
"    ]. The authors postulated that elevation of the optic nerve head from traction of the posterior vitreous may have disrupted the microcirculation and axoplasmic flow leading to optic nerve edema and visual dysfunction. Surgical release of epipapillary vitreous traction via vitrectomy was performed within one month, with visual acuity improvement noted in 15 patients, nine of whom had greater than three lines of improvement.",
"   </p>",
"   <p>",
"    This was an uncontrolled case series. The findings need to be independently confirmed before this treatment should be adopted. Other authors have disputed the findings and conclusions of this report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. However, this study raises the possibility of a role of vitreous traction in the pathogenesis of NAION.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other investigational medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts continue to develop a treatment for NAION. Research has focused on medications that may have neuroprotective effects, ameliorate disc edema and pressure surrounding the optic nerve head, and improve blood flow to areas of ischemia. The development of an animal model of NAION may aid these endeavors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Levodopa",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential role for dopamine in the treatment of NAION is based on its putative neuroprotective and neuromodulatory effects in the retina, optic nerve,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brain, or its activity as a neurotransmitter in the retina. The benefit of levodopa in NAION is not established.",
"   </p>",
"   <p>",
"    In a nonrandomized study, 18 patients with NAION were treated with a three-week course of levodopa within 45 days of vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/43\">",
"     43",
"    </a>",
"    ]. Outcomes were compared with 19 untreated controls. At six months, levodopa-treated patients were more likely to have had three lines or greater improvement in visual acuity than controls (77 versus 20 percent). No improvement in visual fields was noted. The statistical analysis and handling of confounding variables in this study has been criticized [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Levodopa has also been studied for its potential to aid visual recovery in patients with chronic NAION. An unblinded but randomized study in 20 patients with NAION of at least six months duration found that six weeks of levodopa treatment was associated with significant improvement in visual acuity, but had no effect on field loss or color vision [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/45\">",
"     45",
"    </a>",
"    ]. A similar study, performed in 24 patients with a mean duration of NAION of more than 10 months, found no benefit for levodopa on visual outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Brimonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=see_link\">",
"     Brimonidine",
"    </a>",
"    is an alpha-2 agonist that lowers intraocular pressure and is used in the treatment of glaucoma. There have been promising reports from animal studies suggesting that topical brimonidine may have a neuroprotective effect on retinal ganglion cells and reduce optic nerve injury after ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. However, a randomized placebo controlled trial found no therapeutic effect of brimonidine 0.2 percent in 36 patients with acute NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/50\">",
"     50",
"    </a>",
"    ]. Moreover, an open label study of 14 patients treated with brimonidine suggested a trend for worse visual acuity and fields in treated patients compared with matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Citicoline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Citicoline is a putative neuroprotective agent that has been evaluated in the treatment of acute cerebral infarction. In a randomized pilot study, 14 patients with NAION were treated with citicoline 1600 mg per day for 60 days. After 60 and 180 days, these treated patients demonstrated overall improvement in visual acuity compared to baseline, while untreated patients did not [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Intravitreal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravitreal administration of medications offers the promise of delivering targeted medications directly to the source of pathology. However, this route of administration is not without risks, including a small risk of infectious endophthalmitis, retinal detachment, and traumatic cataract estimated at about 0.15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/53\">",
"     53",
"    </a>",
"    ]. None of the agents discussed below is currently recommended in the treatment of NAION.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      &mdash; Intravitreal triamcinolone acetonide (IVTA), a corticosteroid, has been administered to patients with NAION. In one case series of four patients, treatment was associated with marked, early resolution of optic disc swelling, disappearing by week three in all eyes, in contrast to persistence of disc edema in a control group of six patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/54\">",
"       54",
"      </a>",
"      ]. Mean improvements in visual acuity also appeared better with treatment compared with controls; however, treatment was not clearly associated with visual field improvement. In two other small case series of three and four patients, respectively, IVTA was administered with some observed gains in visual acuity, but these case series were not controlled [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. In one case, treatment was complicated by increase in intraocular pressure requiring anti-glaucoma treatment, a complication that occurs in up to 25 percent of patients when IVTA is administered for other indications [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-vascular endothelial growth factor (VEGF) agents &mdash; VEGF is a signaling protein that stimulates angiogenesis and increases microvascular permeability. Anti-VEGF agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      have the potential to reduce vasogenic edema and may play a role in decreasing optic nerve head edema and secondary tissue injury. A recent report described visual improvement in four eyes of four patients after single intravitreal injection of ranibizumab [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/59\">",
"       59",
"      </a>",
"      ]. Another case report describes rapid resolution of vision loss and disc edema in a patient with NAION treated with intravitreal bevacizumab [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/60\">",
"       60",
"      </a>",
"      ]. However, there have been two reports of NAION occurring after intravitreal injection of bevacizumab (for non-NAION indications) at one week and two weeks post-injection [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erythropoietin &mdash; In one case series, 31 patients with NAION received unilateral intravitreal erythropoietin injection (2000 units), within one month of onset of NAION [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/63\">",
"       63",
"      </a>",
"      ]. Visual acuity improvement occurred in 61 percent of patients within the first month. Vision continued to improve up to three months and then deteriorated, but remained significantly better than baseline at the last, six month, follow-up",
"      <span class=\"nowrap\">",
"       examination.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Fibrinogen/LDL apheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen/LDL",
"    apheresis, also known as heparin-induced extracorporeal",
"    <span class=\"nowrap\">",
"     LDL/fibrinogen",
"    </span>",
"    precipitation (HELP) removes fibrinogen, total cholesterol, low density lipoproteins and triglycerides from plasma and has shown promise in the treatment of microvascular disorders, including peripheral artery disease and sudden hearing loss of vascular origin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In a small, randomized, controlled study, 40 patients with recent-onset NAION, were assigned to treatment with HELP or to hemodilution therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/66\">",
"     66",
"    </a>",
"    ]. There was no significant difference in visual outcomes between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;While case reports have suggested a possible benefit for hyperbaric oxygen in the treatment of NAION, these findings have not been confirmed in well-designed studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/67\">",
"     67",
"    </a>",
"    ]. A nonrandomized study compared hyperbaric oxygen treatment in 20 patients with acute NAION with 27 untreated patients and found no significant difference in visual acuity or visual field outcomes in the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known effective therapy proven to prevent NAION in the fellow eye [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. Most patients with NAION are treated with daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and risk factor management.",
"   </p>",
"   <p>",
"    Patients taking medications implicated in the pathogenesis of NAION (eg, phosphodiesterase inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , interferon alpha, sympathomimetics) should be counseled about a possible association and consider alternative medications if available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four retrospective studies have evaluated the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the prevention of NAION in the fellow eye with somewhat mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study compared outcomes in 153 patients who had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      following the development of unilateral NAION and 278 who had not [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/14\">",
"       14",
"      </a>",
"      ]. After five years. the cumulative probability of NAION in the fellow eye was similar in the aspirin and no-aspirin groups (17 and 20 percent respectively).",
"     </li>",
"     <li>",
"      In the IONDT, data on the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      were retrospectively obtained on 326 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/15\">",
"       15",
"      </a>",
"      ]. Twenty percent of aspirin users developed NAION in the fellow eye compared with 13 percent of non-aspirin treated patients.",
"     </li>",
"     <li>",
"      In a case-control study, 33 patients who had developed fellow eye NAION were compared to 67 without recurrence two years after the initial event [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      therapy was associated with a decreased incidence (17 versus 53 percent, relative risk = 0.44) of fellow eye NAION regardless of vascular risk factors.",
"     </li>",
"     <li>",
"      In another case series of 52 patients, 325 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with a reduced frequency of second eye involvement compared to those not treated with aspirin (18 versus 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there isn&rsquo;t sufficient evidence to support",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy as secondary prevention in NAION, many patients with NAION will be appropriately treated with aspirin therapy on the basis of their underlying vasculopathic risk factors that independently place them at risk for cardiovascular disease and stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Associated conditions and medications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients found to have underlying hypercoagulable condition may benefit from anticoagulation as such treatment may prevent future thromboembolic events [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"       \"Management of inherited thrombophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The association between NAION and phosphodiesterase-5 (PDE-5) inhibitors is unproven. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H14#H14\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Phosphodiesterase-5 inhibitors'",
"      </a>",
"      .) Although it is premature to advocate screening for the optic \"disc at risk\" in patients who request PDE-5 inhibitors, some recommend patient counseling about the potential ocular side effects in those men who have suffered an event of NAION in one eye [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. The FDA has advised patients \"to stop taking these medicines, and call a doctor or healthcare provider right away if they experience sudden or decreased vision loss in one or both eyes\", and that people \"taking or considering taking these products [should] inform their health care professionals if they have ever had severe loss of vision, which might reflect a prior episode of NAION\" [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with NAION who are taking other implicated medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , interferon alpha, sympathomimetics) should be counseled about the possible association and alternatives should be considered if available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H13#H13\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with sleep apnea are likely to benefit from treatment, although in one case series of three patients, treatment of sleep apnea did not appear to prevent NAION [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Vascular risk factor management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical control of underlying vasculopathic risk factors (eg, hypertension, diabetes, and smoking) is indicated in the primary prevention of cardiovascular disease and stroke; it is not known whether such interventions decrease the risk of NAION recurrence.",
"   </p>",
"   <p>",
"    Over-aggressive control of systemic arterial hypertension may produce nocturnal hypotension, which is believed to be a risk factor for NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/75\">",
"     75",
"    </a>",
"    ]. Morning administration of blood pressure medications should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Nocturnal hypotension'",
"    </a>",
"    .) Patients with acutely elevated blood pressure should have their blood pressure lowered incrementally rather than abruptly, as this has been described as precipitating NAION in at least one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     VISUAL REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 50 percent of patients with NAION are left with visual acuity less than",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    with constricted visual fields. These patients may benefit from visual rehabilitation offered by low vision services [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new modality called vision restoration therapy (VRT) which uses a computer program to stimulate areas of residual vision in patients with visual field defects has been advocated for patients with low vision. A randomized, double-blind pilot trial to evaluate the effects of VRT on the visual function in 10 NAION patients found a nonsignificant trend toward benefit of visual function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9929/abstract/78\">",
"     78",
"    </a>",
"    ]. However, VRT remains controversial and unproven and so far there is very little evidence to support the use of VRT as part of low vision interventions offered to patients with optic neuropathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAION remains a condition that has an unknown etiology and no known means of effective prevention or treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with acute NAION have a 5 to 10 percent incidence of significant visual acuity worsening over the first several days to few weeks. In most patients, vision then subsequently stabilizes or improves. About one-third of patients will have significant improvement in visual acuity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Visual prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over five years of follow-up, patients with NAION have a low risk (5 to 7 percent) of recurrence in the same eye, and a higher risk of recurrence in the fellow eye (15 to 19 percent). Diabetes and greater severity of NAION in the first eye are risk factors for fellow-eye NAION (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Recurrence'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with NAION do not appear to have a higher mortality or risk for stroke or cardiovascular disease than would otherwise be expected on the basis of their underlying comorbidities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mortality and other vascular events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No treatment for NAION has been shown to improve visual acuity outcomes or reduce the risk of recurrence. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optic nerve sheath decompression surgery has been shown to be not beneficial and is potentially harmful in the treatment of NAION. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Optic Nerve Sheath Decompression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and vascular risk factor management has not been shown to improve visual outcomes or reduce recurrence in patients with NAION, most will be appropriately so-treated to reduce their risk of stroke and cardiovascular events. We also generally advise morning administration of blood pressure medications to avoid nocturnal hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"       \"Overview of primary prevention of coronary heart disease and stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with NAION who are taking implicated medications (phosphodiesterase-5 inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , interferon alpha, sympathomimetics) should be counseled about the possible association and advised to discontinue the medication after sustaining an episode of NAION. Alternative therapies should be considered if available. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Associated conditions and medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/1\">",
"      Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/2\">",
"      Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/3\">",
"      Arnold AC, Hepler RS. Natural history of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 1994; 14:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/4\">",
"      Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 2008; 115:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/5\">",
"      Yee RD, Selky AK, Purvin VA. Outcomes of optic nerve sheath decompression for nonarteritic ischemic optic neuropathy. J Neuroophthalmol 1994; 14:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/6\">",
"      Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000; 118:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/7\">",
"      Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 1995; 273:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/8\">",
"      Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/9\">",
"      Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2003; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/10\">",
"      Danesh-Meyer HV, Savino PJ, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/11\">",
"      Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/12\">",
"      Hayreh SS, Podhajsky PA, Zimmerman B. Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/13\">",
"      Preechawat P, Bruce BB, Newman NJ, Biousse V. Anterior ischemic optic neuropathy in patients younger than 50 years. Am J Ophthalmol 2007; 144:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/14\">",
"      Beck RW, Hayreh SS, Podhajsky PA, et al. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/15\">",
"      Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/16\">",
"      Kupersmith MJ, Frohman L, Sanderson M, et al. Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol 1997; 17:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/17\">",
"      Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology 2008; 115:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/18\">",
"      Boone MI, Massry GG, Frankel RA, et al. Visual outcome in bilateral nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1996; 103:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/19\">",
"      WuDunn D, Zimmerman K, Sadun AA, Feldon SE. Comparison of visual function in fellow eyes after bilateral nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1997; 104:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/20\">",
"      Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/21\">",
"      Guyer DR, Miller NR, Auer CL, Fine SL. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol 1985; 103:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/22\">",
"      Arnold AC, Levin LA. Treatment of ischemic optic neuropathy. Semin Ophthalmol 2002; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/23\">",
"      Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 2010; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/24\">",
"      Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 121:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/25\">",
"      Connolly SE, Gordon KB, Horton JC. Salvage of vision after hypotension-induced ischemic optic neuropathy. Am J Ophthalmol 1994; 117:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/26\">",
"      Stevens WR, Glazer PA, Kelley SD, et al. Ophthalmic complications after spinal surgery. Spine (Phila Pa 1976) 1997; 22:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/27\">",
"      Korzets A, Marashek I, Schwartz A, et al. Ischemic optic neuropathy in dialyzed patients: a previously unrecognized manifestation of calcific uremic arteriolopathy. Am J Kidney Dis 2004; 44:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/28\">",
"      Basile C, Addabbo G, Montanaro A. Anterior ischemic optic neuropathy and dialysis: role of hypotension and anemia. J Nephrol 2001; 14:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/29\">",
"      Winkelmayer WC, Eigner M, Berger O, et al. Optic neuropathy in uremia: an interdisciplinary emergency. Am J Kidney Dis 2001; 37:E23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/30\">",
"      Kim JS, Deputy S, Vives MT, Aviles DH. Sudden blindness in a child with end-stage renal disease. Pediatr Nephrol 2004; 19:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/31\">",
"      Moster ML. Visual loss after coronary artery bypass surgery. Surv Ophthalmol 1998; 42:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/32\">",
"      Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008; 246:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/33\">",
"      Sergott RC, Cohen MS, Bosley TM, Savino PJ. Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol 1989; 107:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/34\">",
"      Soheilian M, Koochek A, Yazdani S, Peyman GA. Transvitreal optic neurotomy for nonarteritic anterior ischemic optic neuropathy. Retina 2003; 23:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/35\">",
"      Friberg TR, Smolinski P, Hill S, Kurup SK. Biomechanical assessment of radial optic neurotomy. Ophthalmology 2008; 115:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/36\">",
"      Beck AP, Ryan EA, Lou PL, Kroll AJ. Controversies regarding radial optic neurotomy for central retinal vein occlusion. Int Ophthalmol Clin 2005; 45:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/37\">",
"      Modarres M, Sanjari MS, Falavarjani KG. Vitrectomy and release of presumed epipapillary vitreous traction for treatment of nonarteritic anterior ischemic optic neuropathy associated with partial posterior vitreous detachment. Ophthalmology 2007; 114:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/38\">",
"      Lee MS, Foroozan R, Kosmorsky GS. Posterior vitreous detachment in AION. Ophthalmology 2009; 116:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/39\">",
"      Soheilian M, Yazdani S. Ischemic optic neuropathy. Ophthalmology 2007; 114:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/40\">",
"      Lovelace K, O'Donnell T, Enzenauer RW. Anterior ischemic optic neuropathy. Ophthalmology 2007; 114:2368; author reply 2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/41\">",
"      Bernstein SL, Guo Y, Slater BJ, et al. Neuron stress and loss following rodent anterior ischemic optic neuropathy in double-reporter transgenic mice. Invest Ophthalmol Vis Sci 2007; 48:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/42\">",
"      Bernstein SL, Guo Y, Kelman SE, et al. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2003; 44:4153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/43\">",
"      Johnson LN, Guy ME, Krohel GB, Madsen RW. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2000; 107:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/44\">",
"      Beck RW. Does Levodopa improve visual function in NAION? Ophthalmology 2000; 107:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/45\">",
"      Johnson LN, Gould TJ, Krohel GB. Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration. Am J Ophthalmol 1996; 121:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/46\">",
"      Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. Int J Clin Pract 2005; 59:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/47\">",
"      Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 2001; 11 Suppl 2:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/48\">",
"      Wen R, Cheng T, Li Y, et al. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16:5986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/49\">",
"      Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/50\">",
"      Wilhelm B, L&uuml;dtke H, Wilhelm H, BRAION Study Group. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 2006; 244:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/51\">",
"      Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION? Br J Ophthalmol 2003; 87:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/52\">",
"      Parisi V, Coppola G, Ziccardi L, et al. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol 2008; 15:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/53\">",
"      Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 2008; 22:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/54\">",
"      Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2007; 27:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/55\">",
"      Jonas JB, Spandau UH, Harder B, Sauder G. Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/56\">",
"      Yaman A, Selver OB, Saatci AO, Soylev MF. Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 2008; 91:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/57\">",
"      Hayreh SS. Intravitreal triamcinolone for nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2008; 28:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/58\">",
"      Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009; 116:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/59\">",
"      Bajin MS, Selver OB, Taskin O, et al. Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 2011; 94:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/60\">",
"      Bennett JL, Thomas S, Olson JL, Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol 2007; 27:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/61\">",
"      Hosseini H, Razeghinejad MR. Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab. J Neuroophthalmol 2009; 29:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/62\">",
"      Ganssauge M, Wilhelm H, Bartz-Schmidt KU, Aisenbrey S. Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2009; 247:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/63\">",
"      Modarres M, Falavarjani KG, Nazari H, et al. Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 2011; 95:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/64\">",
"      Suckf&uuml;ll M, Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002; 360:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/65\">",
"      Ramunni A, Brescia P, Quaranta D, et al. Fibrinogen apheresis in the treatment of peripheral arterial disease. Blood Purif 2007; 25:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/66\">",
"      Haas A, Walzl M, Jesenik F, et al. Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 1997; 235:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/67\">",
"      Boji�� L, Ivanisevi�� M, Gosovi�� G. Hyperbaric oxygen therapy in two patients with non-arteritic anterior optic neuropathy who did not respond to prednisone. Undersea Hyperb Med 2002; 29:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/68\">",
"      Arnold AC, Hepler RS, Lieber M, Alexander JM. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 122:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/69\">",
"      Salomon O, Huna-Baron R, Steinberg DM, et al. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) 1999; 13 ( Pt 3a):357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/70\">",
"      Srinivasan S, Fern A, Watson WH, McColl MD. Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation. Am J Ophthalmol 2001; 131:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/71\">",
"      Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol 2005; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/72\">",
"      Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol 2001; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. FDA updates labeling for Viagra, Cialis, and Levitra for rare post-marketing reports of eye problems www.fda.gov/bbs/topics/NEWS/2005/NEW01201.html/ (Accessed on July 8, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/74\">",
"      Behbehani R, Mathews MK, Sergott RC, Savino PJ. Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure. Am J Ophthalmol 2005; 139:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/75\">",
"      Hayreh SS. Treatment of IOH and risk of visual complications. Arch Intern Med 2002; 162:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/76\">",
"      Stelmack JA, Tang XC, Reda DJ, et al. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol 2008; 126:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/77\">",
"      Jamara R, Potaznick W, Matjucha I. Low vision rehabilitation for a target-shooting marksman with visual field loss and diplopia. Optometry 2008; 79:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9929/abstract/78\">",
"      Jung CS, Bruce B, Newman NJ, Biousse V. Visual function in anterior ischemic optic neuropathy: effect of Vision Restoration Therapy--a pilot study. J Neurol Sci 2008; 268:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5234 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9929=[""].join("\n");
var outline_f9_44_9929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Visual prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mortality and other vascular events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Optic Nerve Sheath Decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Optic neurotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other investigational medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Levodopa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Brimonidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Citicoline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Intravitreal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Fibrinogen/LDL apheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SECONDARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Associated conditions and medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Vascular risk factor management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      VISUAL REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=related_link\">",
"      Optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9930="Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)";
var content_f9_44_9930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9930/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9930/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9930/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9930/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/44/9930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/44/9930/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/44/9930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoaldosteronism should be considered in any patient with persistent hyperkalemia in whom there is no obvious cause such as renal failure or the use of potassium supplements or a potassium-sparing diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The rise in the plasma potassium in this disorder reflects the major role played by aldosterone in urinary potassium excretion. In addition to hyperkalemia, hypoaldosteronism is usually associated with a mild metabolic acidosis with a normal anion gap (ie, a hyperchloremic acidosis) which has been called type 4 renal tubular acidosis.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, etiology, diagnosis, and treatment of hypoaldosteronism will be presented here. The evaluation of patients with hyperkalemia in general is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232948\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestations in patients with hypoaldosteronism are hyperkalemia and a mild hyperchloremic metabolic acidosis. Hypoaldosteronism should be considered in any patient with persistent hyperkalemia in whom there is no obvious cause such as renal failure or the use of potassium supplements or a potassium-sparing diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although aldosterone also promotes sodium retention, hypoaldosteronism is",
"    <strong>",
"     not",
"    </strong>",
"    typically associated with prominent sodium wasting (except in young children) because of the compensatory action of other sodium-retaining factors (such as angiotensin II and norepinephrine) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1\">",
"     1",
"    </a>",
"    ]. Hyponatremia is also uncommon in patients with isolated aldosterone deficiency, since there is no hypovolemia-induced stimulation of ADH release and because plasma cortisol, a tonic inhibitor of ADH release, is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1\">",
"     1",
"    </a>",
"    ]. When hyponatremia is present, primary adrenal insufficiency should be suspected. In this disorder, the concurrent lack of cortisol is a potent stimulus to ADH secretion, leading to water retention and a fall in the plasma sodium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233165\">",
"    <span class=\"h2\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone acts by increasing the number of open sodium channels in the luminal membrane of the principal cells in the cortical collecting tubule, leading to increased sodium reabsorption. The ensuing removal of sodium from the tubular fluid makes the lumen electronegative, thereby creating an electrical gradient that favors the secretion of cellular potassium into the lumen through potassium channels in the luminal membrane (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most patients with hypoaldosteronism have only a moderate decrease in aldosterone release or effect, with a small increase in plasma potassium concentration. The development of overt hyperkalemia is most common in aldosterone deficient patients with other risk factors that further impair the efficiency of potassium excretion, such as renal insufficiency, reduced renal perfusion, or the use of medications that interfere with potassium handling such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), or renin inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233172\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia in hypoaldosteronism is usually associated with a mild metabolic acidosis; the anion gap is typically normal (ie, a hyperchloremic acidosis) unless there is concurrent renal insufficiency. This condition has been called type 4 renal tubular acidosis and appears to be due primarily to decreased urinary ammonium excretion.",
"   </p>",
"   <p>",
"    Three mechanisms have been proposed to explain decreased ammonium excretion in this disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When urinary potassium excretion is impaired, some of the excess potassium enters the cells, with electroneutrality being maintained in part by the movement of cellular sodium and hydrogen ions into the extracellular fluid. The ensuing intracellular alkalosis in the kidney would then diminish ammonium production in the proximal tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ammonium is normally reabsorbed into the medullary interstitium and is then resecreted into the medullary collecting tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/4\">",
"       4",
"      </a>",
"      ]. Hyperkalemia decreases medullary cycling by inhibiting ammonium reabsorption in the thick ascending limb. Potassium and ammonium compete for a common transporter in the luminal membrane which can function as a Na-K-2Cl or a Na-NH4-2Cl transporter. A review of loop transport mechanisms can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"       \"Diuretics and calcium balance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the collecting duct, the basolateral Na-K-ATPase can also function as a Na-NH4 exchanger, permitting uptake of NH4 from the interstitium and subsequent secretion into the urine [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. However, potassium competes with NH4 for this exchanger, and therefore hyperkalemia impairs the capacity of the pump to carry NH4 into the cell.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of hypoaldosteronism include both acquired and, less often, inherited disorders, which can affect adrenal aldosterone synthesis or renal (and perhaps adrenal) renin release (",
"    <a class=\"graphic graphic_table graphicRef82440 \" href=\"UTD.htm?41/0/41995\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2\">",
"     2",
"    </a>",
"    ]. Plasma renin activity is usually increased in those disorders in which there is diminished aldosterone action with the exception of the different forms of hyporeninemic hypoaldosteronism.",
"   </p>",
"   <p>",
"    The most common acquired causes of hypoaldosteronism are hyporeninemic hypoaldosteronism, pharmacologic inhibition of angiotensin II, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy. Primary adrenal insufficiency is an infrequent cause.",
"   </p>",
"   <p>",
"    In addition, the clinical features of aldosterone deficiency can be mimicked by disorders that reduce the renal response to aldosterone, the most common being pharmacological inhibition of the epithelial sodium channel in the cortical collecting tubule with potassium-sparing diuretics. The following discussion is divided according to the primary mechanism: reduced aldosterone production or aldosterone resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25008898\">",
"    <span class=\"h2\">",
"     Reduced aldosterone production",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Hyporeninemic hypoaldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of hyporeninemic hypoaldosteronism is characterized by both diminished renin release and an intraadrenal defect, which, in concert, result in decreased systemic and intraadrenal angiotensin II production. Reduced angiotensin II production contributes to the decline in aldosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The intraadrenal defect may involve the local renin-angiotensin system, since there is evidence that angiotensin II produced locally within the adrenal gland may stimulate the release of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/7\">",
"     7",
"    </a>",
"    ]. Many of these patients also have diminished responsiveness to aldosterone as evidenced by the need for a higher physiologic replacement mineralocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyporeninemic hypoaldosteronism is most common in patients with mild to moderate renal insufficiency due to diabetic nephropathy or chronic interstitial nephritis, but can also occur with acute glomerulonephritis, and in patients taking nonsteroidal antiinflammatory drugs or calcineurin inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25009310\">",
"    <span class=\"h4\">",
"     Diabetes and renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low plasma renin activity is common in diabetic patients due, in part, to a defect in the conversion of the precursor prorenin to active renin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of diabetic nephropathy\", section on 'Prorenin'",
"    </a>",
"    .) Volume expansion induced by diabetic and other chronic renal diseases also may play a contributory role; the increase in atrial natriuretic peptide release in these patients can suppress both the release of renin and hyperkalemia-induced secretion of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar hemodynamic and humoral changes occur in acute glomerulonephritis (such as postinfectious glomerulonephritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/10\">",
"     10",
"    </a>",
"    ]. These changes can lead to hyperkalemia that responds to mineralocorticoid replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/11\">",
"     11",
"    </a>",
"    ]. Recovery of renal function within 1 to 2 weeks is associated with restoration of normal potassium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) have two effects that promote the development of hyperkalemia: they reduce renal renin secretion, which is normally mediated in part by locally produced prostaglandins; and they impair angiotensin II-induced release of aldosterone. A NSAID-induced reduction in glomerular filtration rate can also contribute to the rise in plasma potassium. The magnitude of the effect of NSAIDs on the plasma potassium was evaluated in a study of 50 hospitalized patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy was initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/12\">",
"     12",
"    </a>",
"    ]. The serum potassium rose by 0.5 to 0.9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 34 percent and by 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more in 26 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=see_link&amp;anchor=H3#H3\">",
"     \"NSAIDs: Electrolyte complications\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25009470\">",
"    <span class=\"h4\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    leads to hyperkalemia in 15 to 25 percent of renal transplant recipients, due in part to diminished secretion of, as well as responsiveness to, aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The latter effect may be mediated by reduced mineralocorticoid receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately 75 percent of transplant recipients who receive immunosuppressive therapy with cyclosporine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    develop hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link&amp;anchor=H9#H9\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Angiotensin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar considerations apply to angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and direct renin inhibitors, which diminish aldosterone release by impairing the conversion of angiotensin I to angiotensin II both systemically and perhaps within the adrenal zona glomerulosa, by blocking angiotensin II action at the receptor, and by inhibiting renin activity, respectively. In addition, the normal stimulatory effect of an elevation in the plasma potassium concentration on aldosterone release may be mediated in part by the adrenal generation of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, an ACE inhibitor may decrease both angiotensin II- and potassium-mediated aldosterone release [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike some of the other drugs discussed in this section, renin secretion is increased with ACE inhibitors. ACE inhibitors usually raise the plasma potassium concentration by less than 0.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in patients with relatively normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/18\">",
"     18",
"    </a>",
"    ]. However, more prominent hyperkalemia can occur in patients with renal insufficiency or those taking a potassium-sparing diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/18\">",
"     18",
"    </a>",
"    ]. Similar considerations apply to patients treated with ARBs. The hyperkalemic effect can also be seen in patients on maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The latter interaction is becoming an increasingly common problem because ACE inhibitors, ARBs, and the potassium-sparing diuretics that block the mineralocorticoid receptor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) improve survival in patients with heart failure. The frequency and magnitude of the combined effect on plasma potassium is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Risk of hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147617687\">",
"    <span class=\"h3\">",
"     Heparin and low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has a direct toxic effect on the adrenal zona glomerulosa cells, which may be mediated by a reduction in the number and affinity of adrenal angiotensin II receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. Even low-dose heparin (5000 units administered subcutaneously twice daily) can lead to a substantial reduction in plasma aldosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/21\">",
"     21",
"    </a>",
"    ]. It has been estimated that a greater than normal plasma potassium concentration occurs in 7 percent of patients. Severe hyperkalemia occurs only if some other impairment in potassium excretion is present, such as renal insufficiency, or use of an ACE inhibitor, ARB, or a potassium-sparing diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has a similar effect on potassium balance. In one report of 81 patients treated with low molecular weight heparin as prophylaxis for venous thromboembolism, the plasma potassium concentration increased slightly (a mean of 5 to 10 percent); the highest rise (from 5.11 to 5.70",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was recorded in a patient with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/22\">",
"     22",
"    </a>",
"    ]. A similar increase in plasma potassium concentration was noted in another series, with the value exceeding 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 9 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147617694\">",
"    <span class=\"h3\">",
"     Primary adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary adrenal insufficiency is associated with lack of cortisol as well as aldosterone. Pituitary disease, in comparison, does not lead to hypoaldosteronism since corticotropin (ACTH) does not have a major role in the regulation of aldosterone release. Primary adrenal insufficiency can result from autoimmune adrenalitis, infectious adrenalitis (eg, HIV), and other disorders. Primary adrenal insufficiency is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232731\">",
"    <span class=\"h3\">",
"     Severe illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoaldosteronism due to decreased adrenal production can occur in critically ill patients. Volume expansion may play a contributory role in some patients. In addition, the stress-induced hypersecretion of ACTH may diminish aldosterone synthesis by diverting substrate to the production of cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25009618\">",
"    <span class=\"h3\">",
"     Inherited disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited forms of hypoaldosteronism due to reduced aldosterone production include congenital isolated hypoaldosteronism and pseudohypoaldosteronism type 2. In contrast, pseudohypoaldosteronism type 1 is associated with aldosterone resistance. (See",
"    <a class=\"local\" href=\"#H654524127\">",
"     'Pseudohypoaldosteronism type 1'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Congenital isolated hypoaldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, hypoaldosteronism can result from a deficiency of enzymes required for aldosterone synthesis, which may or may not be associated with concurrent abnormalities in cortisol and androgen production. Examples include genetic defects in aldosterone synthase (P450c11as, pure hypoaldosteronism) and P450c21 (21-hydroxylase, hypocortisolism with variable virilizing) (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2,25,26\">",
"     2,25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital isolated hypoaldosteronism is a rare inherited disorder that is transmitted as an autosomal recessive trait. The clinical presentation is typical of aldosterone deficiency; affected infants have recurrent hypovolemia, salt wasting, and failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The usual defect in this disorder is in the activity of the terminal enzyme in the aldosterone biosynthetic pathway, aldosterone synthase (CYP11B2) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Two types of aldosterone synthase defects can occur, reflecting its two enzymatic functions: CYP11B2 type I, characterized by impaired hydroxylation of corticosterone at the 18-carbon position; and CYP11B2 type II, characterized by impaired conversion of the 18-hydroxyl group to an aldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aldosterone synthase type I deficiency would be expected to produce low plasma concentrations of products derived from corticosterone (18-hydroxycorticosterone and aldosterone) and low urinary excretion of their metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/29\">",
"     29",
"    </a>",
"    ]; in contrast, aldosterone synthase type II deficiency should be associated with hypoaldosteronism but high plasma concentrations of 18-hydroxycorticosterone and increased urinary excretion of the major metabolite of 18-hydroxycorticosterone, tetrahydro-18-hydroxy,11-dehydrocorticosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Thus, the ratio of plasma 18-hydroxycorticosterone to plasma aldosterone can be used to differentiate between the two disorders: &lt;10 in type I; and &gt;100 in type II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the cases originally thought to be caused by aldosterone synthase type I defects have been shown to represent type II deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This finding is not surprising, because mitochondrial P450c11, as the product of a single gene, catalyzes 11-beta-hydroxylation and both of the reactions convert deoxycorticosterone to aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/32\">",
"     32",
"    </a>",
"    ]. The CYP11B2 gene is located on chromosome 8q24.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/33\">",
"     33",
"    </a>",
"    ] and is the site of mutations causing both type I and type II aldosterone synthase deficiency. CYP11B2 is located adjacent to CYP11B1, which encodes P-450c11, the enzyme that converts deoxycortisol to cortisol (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some patients with aldosterone synthase type I deficiency have a 5-nucleotide deletion in exon 1 leading to a frameshift and premature stop codon; as a result they produce no functional aldosterone synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/26,34\">",
"     26,34",
"    </a>",
"    ]. Other patients have a point mutation causing an R384P substitution; the arginine (R) is highly conserved and presumably important for enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/35\">",
"     35",
"    </a>",
"    ]. An L461P and a nonsense E255X mutation have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Twin boys with type I deficiency had simultaneous E198D and V386A mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with aldosterone synthase type II deficiency have",
"    <strong>",
"     one of",
"    </strong>",
"    two point mutations resulting in R181W and V386A substitutions that do not affect 11-beta-hydroxylase activity, but reduce 18-hydroxylase activity and abolish 18-oxidase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/26,39\">",
"     26,39",
"    </a>",
"    ]. A mutation that greatly reduces the activity of the enzyme in vitro is associated with normal aldosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/39\">",
"     39",
"    </a>",
"    ]; thus, only the most severe enzyme deficiencies are manifested clinically.",
"   </p>",
"   <p>",
"    A number of kindreds with a similar presentation of familial hyperreninemic hypoaldosteronism have no mutation in CYP11B2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/28\">",
"     28",
"    </a>",
"    ]. The genetic abnormality in these families is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Pseudohypoaldosteronism type 2 (Gordon's syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoaldosteronism type 2 (PHA2) (MIM #145260), also called Gordon's syndrome or familial hyperkalemic hypertension, is characterized by hypertension, hyperkalemia, metabolic acidosis, normal renal function, and low or low-normal plasma renin activity and aldosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. In contrast, pseudohypoaldosteronism type 1 produces aldosterone resistance. (See",
"    <a class=\"local\" href=\"#H654524127\">",
"     'Pseudohypoaldosteronism type 1'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hyperkalemia and hypertension in PHA2 are caused by abnormalities in WNK kinases, proteins that localize to the distal nephron and affect the thiazide-sensitive Na-Cl cotransporter (",
"    <a class=\"graphic graphic_figure graphicRef64975 \" href=\"UTD.htm?36/27/37309\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Mutations affecting either WNK4 or WNK1 result in increased chloride reabsorption in the distal nephron, thereby reducing lumen electronegativity and lowering the force for potassium secretion. These mutations also result in decreased expression of the potassium channels through which potassium enters the collecting duct.",
"   </p>",
"   <p>",
"    Mutations affecting WNK4 and WNK1 can result in similar phenotypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disruptions in WNK4 are transmitted as an autosomal dominant trait. Wild-type (normal) WNK4 inhibits the surface expression of the thiazide sensitive Na-Cl cotransporter in the luminal membrane of the distal tubule by 50 to 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/46-49\">",
"       46-49",
"      </a>",
"      ]. Missense mutations in the WNK4 gene result in a mutant protein with decreased inhibitor activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/50\">",
"       50",
"      </a>",
"      ], resulting in increased expression of the Na-Cl cotransporter and hyperplasia of the distal convoluted tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Wild-type WNK4 also stimulates clathrin-dependent endocytosis of potassium channels in the collecting duct [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/51\">",
"       51",
"      </a>",
"      ], thereby decreasing the surface expression of potassium channels. Endocytosis of potassium channels is enhanced by defective WNK4 proteins, resulting in fewer functioning potassium channels.",
"      <br/>",
"      <br/>",
"      Thus, mutant WNK4 increases sodium chloride reabsorption in the distal tubule and decreases potassium secretion in the collecting tubule.",
"     </li>",
"     <li>",
"      WNK1 is expressed in many tissues including the distal tubule and collecting tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/52\">",
"       52",
"      </a>",
"      ]. Wild-type WNK1 inhibits the function of WNK4 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. Thus, a gain-of-function mutation in WNK1 would further inhibit WNK4 activity, resulting in increased expression of the Na-Cl cotransporter in the distal tubule and reduced expression of potassium channels in the collecting tubule. In addition to inhibiting WNK4, WNK1 may have direct effects on potassium channel expression in the collecting duct [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disease-causing mutations in both WNK1 and WNK4 also increase chloride permeability via the paracellular pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232851\">",
"    <span class=\"h5\">",
"     Genotype-phenotype correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased sodium chloride reabsorption in the distal tubule leads to volume expansion and hypertension and diminished renin secretion. In addition, increased distal sodium chloride reabsorption decreases sodium and water delivery to the potassium and hydrogen secreting cells in the cortical collecting tubule, thereby reducing potassium and hydrogen excretion. The ability of collecting tubule cells to secrete potassium is also impaired by increased chloride permeability in the distal tubule, which reduces lumen electronegativity and lowers the driving force for potassium secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/41\">",
"     41",
"    </a>",
"    ]. The defect in potassium secretion is compounded by reduced expression of potassium channels in the collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/51,55\">",
"     51,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with this hypothesis is the observation that, in the presence of persistent mineralocorticoid excess, the administration of sodium chloride does not increase potassium excretion as it does in normal subjects; however, giving sodium with a nonreabsorbable anion, such as sulfate or bicarbonate, produced a marked increase in potassium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/41\">",
"     41",
"    </a>",
"    ]. An alternative hypothesis is that the principal cause of hyperkalemia, at least with WNK4 mutations, is impaired cortical collecting potassium channel activity via enhanced cell surface retrieval [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/51,55\">",
"     51,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a mouse model of pseudohypoaldosteronism type 2, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    and knockout of the Na-Cl cotransporter reversed the abnormal phenotype induced by WNK4 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, pseudohypoaldosteronism type 2 due to WNK4 and WNK1 mutations is the mirror image of Gitelman syndrome. The latter disorder is due to a loss-of-function mutation in the distal Na-Cl cotransporter resulting in hypokalemia and metabolic alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654523416\">",
"    <span class=\"h2\">",
"     Aldosterone resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone resistance is most often due to the administration of potassium-sparing diuretics and certain antibiotics that inhibit the collecting tubule sodium channel. A rare cause is the inherited disorder, pseudohypoaldosteronism type 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654523591\">",
"    <span class=\"h3\">",
"     Inhibition of the epithelial sodium channel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic inhibition of the epithelial sodium channel in the collecting tubule, which is the site of action of aldosterone (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ), may be induced by potassium-sparing diuretics and certain antibiotics. The net effect is aldosterone resistance rather than reduced aldosterone production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654523598\">",
"    <span class=\"h4\">",
"     Potassium-sparing diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium-sparing diuretics act by either antagonizing the action of aldosterone on the collecting tubule cells by competing for the aldosterone receptor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) or by closing the sodium channels in the luminal membrane (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    and probably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654523605\">",
"    <span class=\"h4\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    (usually given as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , can also cause hyperkalemia by closing the epithelial sodium channels in the collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/56-61\">",
"     56-61",
"    </a>",
"    ]. Trimethoprim-induced hyperkalemia is dose-dependent, seen primarily at the very high doses used in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    can raise the plasma potassium concentration even when used in conventional doses, particularly in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/59,60,62,63\">",
"     59,60,62,63",
"    </a>",
"    ]. As an example, one study reviewed the course of 80 patients without renal insufficiency or another cause of altered potassium homeostasis, who were treated for at least five days with conventional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/59\">",
"     59",
"    </a>",
"    ]. Plasma potassium concentration rose by a mean of 1.2",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    from 3.9 to 5.1",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    21 percent of patients had a plasma potassium concentration &ge;5.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The peak effect was at four to five days. Patients with mild renal insufficiency may be at risk for more severe hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/60\">",
"     60",
"    </a>",
"    ]. As previously mentioned, ammonia production is inhibited with the increased potassium concentration, thereby resulting in type 4 renal tubular acidosis.",
"   </p>",
"   <p>",
"    Elderly patients who are on ACE inhibitors or ARBs are at particularly high risk of developing hyperkalemia when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    . This was shown in a case control study of 371 individuals 66 years or older who were receiving continuous therapy with ACE inhibitors or ARBs and were hospitalized with hyperkalemia within 14 days after starting an antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/64\">",
"     64",
"    </a>",
"    ]. Compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , the use of trimethoprim sulfamethoxazole was associated with an almost sevenfold increased risk of hyperkalemia-associated hospitalization. Although fewer than 15 percent of the cases in the cohort had a documented history of renal disease, approximately half had diabetes, suggesting that hyporeninemic hypoaldosteronism due to undiagnosed diabetic nephropathy may have contributed to hyperkalemia. In addition, other drugs may have contributed to hyperkalemia in this study since approximately one-third were also taking NSAIDs, beta-adrenergic blockers, or potassium-sparing diuretics. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Hyporeninemic hypoaldosteronism'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654524127\">",
"    <span class=\"h3\">",
"     Pseudohypoaldosteronism type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoaldosteronism type 1 (PHA 1) is a rare hereditary disorder characterized by resistance to the actions of aldosterone. In contrast, pseudohypoaldosteronism type 2 is associated with reduced aldosterone production because of volume expansion associated with the disorder. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two different modes of inheritance with different mechanisms and clinical manifestations have been described in PHA 1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive PHA 1 (MIM #264350), affects the collecting tubule sodium channel (also called the epithelial sodium channel, or ENaC). The defect is permanent and affects all aldosterone target organs (including the renal collecting tubule, colon, and salivary glands). This disorder is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H8#H8\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Pseudohypoaldosteronism type 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal dominant or sporadic PHA 1 (MIM #177735), affects the mineralocorticoid receptor in most patients. The defect is limited to the kidney, produces milder salt wasting than the autosomal recessive form of PHA 1 disease, and often improves with age. More than 50 different loss-of-function mutations in the gene encoding (NR3C2) the mineralocorticoid receptor have been reported including nonsense, frameshift, and splice site mutations as well as deletions, all leading to an abnormal protein [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/65-72\">",
"       65-72",
"      </a>",
"      ]. Other mutations affect binding of aldosterone to the receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with the recessive form, autosomal dominant pseudohypoaldosteronism type 1 is typically associated with milder clinical symptoms that may remit over time [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. However, severe neonatal manifestations (hyperkalemia, hyponatremia and failure to thrive) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/67\">",
"     67",
"    </a>",
"    ]. The clinical presentation does not correlate well with the specific genotype. Some patients with autosomal dominant pseudohypoaldosteronism type 1 do not have mutations in the mineralocorticoid receptor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/69-71,73\">",
"     69-71,73",
"    </a>",
"    ]. In two series, such mutations were not found in 15 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/69,71\">",
"     69,71",
"    </a>",
"    ]. The causative genes have not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3640046\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF HYPOALDOSTERONISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected to have hypoaldosteronism should be questioned about the use of any drug or the presence of a disease that can impair aldosterone release, such as a nonsteroidal antiinflammatory drug, an angiotensin inhibitor, a calcineurin inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , beta-blockers, or HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2\">",
"     2",
"    </a>",
"    ]. As discussed above, other causes include hyporeninemic hypoaldosteronism (most often associated with diabetes and chronic kidney disease), primary adrenal insufficiency, an adrenal enzyme defect (most often CYP11B2 [aldosterone synthase, P450c11as] deficiency), or the rare genetic disorders pseudohypoaldosteronism type 1 and type 2.",
"   </p>",
"   <p>",
"    The different causes of hypoaldosteronism can be differentiated by measurement of plasma renin activity (PRA), serum aldosterone, and serum cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2\">",
"     2",
"    </a>",
"    ]. These tests should be performed after the administration of a loop diuretic or three hours in the upright position, which will increase renin and aldosterone release in normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=see_link\">",
"     \"Assays of the renin-angiotensin-aldosterone system in adrenal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyporeninemic hypoaldosteronism most often occurs in patients 50 to 70 years of age with diabetic nephropathy or chronic tubulointerstitial disease who have mild to moderate renal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1\">",
"       1",
"      </a>",
"      ]. It is associated with a low PRA in most but not all cases, a low serum aldosterone concentration, and a normal serum cortisol concentration.",
"     </li>",
"     <li>",
"      Patients with primary adrenal insufficiency have low serum aldosterone and cortisol concentrations, but high PRA due to volume depletion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension.",
"     </li>",
"     <li>",
"      Children with an adrenal enzyme deficiency fall into one of two categories. Those with one of the forms of congenital adrenal hyperplasia (ie, CYP21A2 [21-hydroxylase], CYP17 [17-hydroxylase] or 3-beta-hydroxysteroid dehydrogenase deficiency, or congenital lipoid hyperplasia) have a concurrent defect in cortisol synthesis. Thus, their serum values are similar to those in primary adrenal insufficiency, but adrenal androgen synthesis may be increased, leading to virilization [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In comparison, children with congenital isolated (primary) hypoaldosteronism have a defect in one of the two steps (both of which are mediated by the same enzyme, CYP11B2) that are involved in the production of aldosterone: the addition of a hydroxyl group at the 18-carbon position, and the subsequent oxidation of this hydroxyl group to an aldehyde group [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/27\">",
"       27",
"      </a>",
"      ]. However, some kindreds do not have mutations in CYP11B2 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In both congenital adrenal hyperplasia and congenital isolated hypoaldosteronism, the serum aldosterone concentration is low, the serum cortisol concentration is normal, and the PRA is high. The diagnosis of congenital isolated hypoaldosteronism can be confirmed by measurement of serum 11-deoxycorticosterone, corticosterone, 18-hydroxycorticosterone, 18-hydroxydeoxycorticosterone, and aldosterone [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Congenital isolated hypoaldosteronism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with the rare syndrome of pseudohypoaldosteronism type 1 have high PRA and serum aldosterone concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/75\">",
"       75",
"      </a>",
"      ]. Infants with the autosomal recessive variant, in which the epithelial sodium channel is abnormal, may present with a miliaria papular rash, due presumably to a high sodium concentration in sweat [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/76\">",
"       76",
"      </a>",
"      ]. This is not seen in patients with the autosomal dominant form, who usually have loss-of-function mutations in the mineralocorticoid receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/71\">",
"       71",
"      </a>",
"      ]. In this condition, therapy with conventional doses of a mineralocorticoid is usually ineffective. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H9#H9\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Autosomal recessive disease'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H25009618\">",
"       'Inherited disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkalemic patients in whom all of the above disorders have been excluded and in whom renal function is not markedly impaired, probably have a selective potassium secretory defect or the hyperkalemic form of distal renal tubular acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate therapy for hypoaldosteronism varies with the cause of the hormone deficiency. Patients with primary adrenal insufficiency, for example, should receive mineralocorticoid replacement therapy (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    at a dose of 0.05 to 0.2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to correct the hyperkalemia and with 0.9 percent saline to correct symptomatic hypovolemia. Primary adrenal insufficiency should also be treated with a glucocorticoid, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , to correct the cortisol deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     Fludrocortisone",
"    </a>",
"    is also effective in patients with hyporeninemic hypoaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/1\">",
"     1",
"    </a>",
"    ]. The typical dose required to normalize the serum potassium is 0.2 to 1",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    substantially higher than the dose in primary adrenal insufficiency. It is therefore likely that these patients have some component of aldosterone resistance, presumably due to the underlying renal disease.",
"   </p>",
"   <p>",
"    Despite its efficacy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    is often not used in hyporeninemic hypoaldosteronism because many patients with this disorder have hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema, problems that can be exacerbated by mineralocorticoid replacement. In this setting, use of a low potassium diet and, if necessary, a loop or thiazide-type diuretic will usually control the hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/44/9930/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=see_link\">",
"     \"Patient information: Low potassium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2155353\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoaldosteronism should be considered in any patient with persistent hyperkalemia in whom there is no obvious cause such as renal failure or the use of potassium supplements or a potassium-sparing diuretic. In addition to hyperkalemia, hypoaldosteronism is usually associated with a mild metabolic acidosis with a normal anion gap (ie, a hyperchloremic acidosis). This condition has been called type 4 renal tubular acidosis. (See",
"      <a class=\"local\" href=\"#H232948\">",
"       'Pathophysiology and clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aldosterone acts by increasing the number of open sodium channels in the luminal membrane of the principal cells in the cortical collecting tubule, leading to increased sodium reabsorption. The ensuing removal of sodium from the tubular fluid makes the lumen electronegative, thereby creating an electrical gradient that favors the secretion of cellular potassium into the lumen through potassium channels in the luminal membrane (",
"      <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"       figure 1",
"      </a>",
"      ). Decreased aldosterone effect leads to retention of potassium. (See",
"      <a class=\"local\" href=\"#H233165\">",
"       'Hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type 4 renal tubular acidosis and appears to be due primarily to a hyperkalemia-induced decreased urinary ammonium excretion. (See",
"      <a class=\"local\" href=\"#H233172\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of hypoaldosteronism include both disorders that can reduce aldosterone synthesis, and the syndrome can be mimicked by disorders that impair the renal response to aldosterone (aldosterone resistance) (",
"      <a class=\"graphic graphic_table graphicRef82440 \" href=\"UTD.htm?41/0/41995\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major causes of impaired aldosterone production include hyporeninemic hypoaldosteronism, pharmacologic inhibition of renin or angiotensin II,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy, and primary adrenal insufficiency (see",
"      <a class=\"local\" href=\"#H25008898\">",
"       'Reduced aldosterone production'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyporeninemic hypoaldosteronism is most common in patients with mild to moderate renal insufficiency due to diabetic nephropathy or chronic interstitial nephritis, but can also occur with acute glomerulonephritis, and in patients taking nonsteroidal antiinflammatory drugs or calcineurin inhibitors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hyporeninemic hypoaldosteronism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and direct renin inhibitors diminish aldosterone release by impairing the conversion of angiotensin I to angiotensin II both systemically and perhaps within the adrenal zona glomerulosa, by blocking angiotensin II action at the receptor, and by inhibiting renin activity, respectively. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Angiotensin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      therapy, which has a direct toxic effect on the adrenal zona glomerulosa cells, can lead to a substantial reduction in plasma aldosterone concentrations. (See",
"      <a class=\"local\" href=\"#H147617687\">",
"       'Heparin and low molecular weight heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary adrenal insufficiency is associated with lack of both aldosterone and cortisol. (See",
"      <a class=\"local\" href=\"#H147617694\">",
"       'Primary adrenal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited disorders, which are less common, include congenital isolated hypoaldosteronism and pseudohypoaldosteronism type 2 (Gordon's syndrome). (See",
"      <a class=\"local\" href=\"#H25009618\">",
"       'Inherited disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major cause of aldosterone resistance is pharmacologic inhibition of the epithelial sodium channel in the collecting tubule, due either to potassium-sparing diuretics or antibiotics (especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      ). Pseudohypoaldosteronism type 1 is a rare genetic disorder characterized by resistance to the actions of aldosterone. (See",
"      <a class=\"local\" href=\"#H654523416\">",
"       'Aldosterone resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected to have hypoaldosteronism should be questioned about the use of any drug or the presence of a disease that can impair aldosterone release, such as a nonsteroidal antiinflammatory drug, an angiotensin inhibitor, a calcineurin inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , or HIV infection. The different causes of hypoaldosteronism can be differentiated by measurement of plasma renin activity, serum aldosterone, and serum cortisol. These tests should be performed after the administration of a loop diuretic or three hours in the upright position, which will increase renin and aldosterone release in normal individuals. (See",
"      <a class=\"local\" href=\"#H3640046\">",
"       'Diagnosis of hypoaldosteronism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate therapy for hypoaldosteronism usually includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      , but the dose varies with the cause of the hormone deficiency. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19248731\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to acknowledge Dr. Lynnette Nieman, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/1\">",
"      DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.900.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/3\">",
"      Rodr&iacute;guez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 2002; 13:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/4\">",
"      DuBose TD Jr, Good DW. Chronic hyperkalemia impairs ammonium transport and accumulation in the inner medulla of the rat. J Clin Invest 1992; 90:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/5\">",
"      Weiner ID, Verlander JW. Role of NH3 and NH4+ transporters in renal acid-base transport. Am J Physiol Renal Physiol 2011; 300:F11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/6\">",
"      Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol 2009; 20:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/7\">",
"      Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology 1991; 129:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/8\">",
"      Lush DJ, King JA, Fray JC. Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression. Kidney Int 1993; 43:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/9\">",
"      Clark BA, Brown RS, Epstein FH. Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in man. J Clin Endocrinol Metab 1992; 75:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/10\">",
"      Rodr&iacute;guez-Iturbe B, Colic D, Parra G, Gutkowska J. Atrial natriuretic factor in the acute nephritic and nephrotic syndromes. Kidney Int 1990; 38:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/11\">",
"      Don BR, Schambelan M. Hyperkalemia in acute glomerulonephritis due to transient hyporeninemic hypoaldosteronism. Kidney Int 1990; 38:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/12\">",
"      Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed) 1985; 291:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/13\">",
"      Bantle JP, Nath KA, Sutherland DE, et al. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med 1985; 145:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/14\">",
"      Kamel KS, Ethier JH, Quaggin S, et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1992; 2:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/15\">",
"      Heering PJ, Kurschat C, Vo DT, et al. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Clin Transplant 2004; 18:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/16\">",
"      Kaplan B, Wang Z, Abecassis MM, et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation 1996; 62:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/17\">",
"      Pratt JH. Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. J Clin Invest 1982; 70:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/18\">",
"      Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/19\">",
"      Knoll GA, Sahgal A, Nair RC, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/20\">",
"      Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995; 98:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/21\">",
"      Sherman RA, Ruddy MC. Suppression of aldosterone production by low-dose heparin. Am J Nephrol 1986; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/22\">",
"      Canova CR, Fischler MP, Reinhart WH. Effect of low-molecular-weight heparin on serum potassium. Lancet 1997; 349:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/23\">",
"      Koren-Michowitz M, Avni B, Michowitz Y, et al. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf 2004; 13:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/24\">",
"      Braley LM, Adler GK, Mortensen RM, et al. Dose effect of adrenocorticotropin on aldosterone and cortisol biosynthesis in cultured bovine adrenal glomerulosa cells: in vitro correlate of hyperreninemic hypoaldosteronism. Endocrinology 1992; 131:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/25\">",
"      White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994; 331:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/26\">",
"      Shizuta Y, Kawamoto T, Mitsuuchi Y, et al. Inborn errors of aldosterone biosynthesis in humans. Steroids 1995; 60:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/27\">",
"      Ulick S, Wang JZ, Morton DH. The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. J Clin Endocrinol Metab 1992; 74:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/28\">",
"      White PC. Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol 2004; 217:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/29\">",
"      Veldhuis JD, Melby JC. Isolated aldosterone deficiency in man: acquired and inborn errors in the biosynthesis or action of aldosterone. Endocr Rev 1981; 2:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/30\">",
"      Lee PD, Patterson BD, Hintz RL, Rosenfeld RG. Biochemical diagnosis and management of corticosterone methyl oxidase type II deficiency. J Clin Endocrinol Metab 1986; 62:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/31\">",
"      Peter M, Partsch CJ, Sippell WG. Multisteroid analysis in children with terminal aldosterone biosynthesis defects. J Clin Endocrinol Metab 1995; 80:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/32\">",
"      Yanagibashi K, Haniu M, Shively JE, et al. The synthesis of aldosterone by the adrenal cortex. Two zones (fasciculata and glomerulosa) possess one enzyme for 11 beta-, 18-hydroxylation, and aldehyde synthesis. J Biol Chem 1986; 261:3556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/33\">",
"      Taymans SE, Pack S, Pak E, et al. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab 1998; 83:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/34\">",
"      Mitsuuchi Y, Kawamoto T, Miyahara K, et al. Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 1993; 190:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/35\">",
"      Geley S, J&ouml;hrer K, Peter M, et al. Amino acid substitution R384P in aldosterone synthase causes corticosterone methyloxidase type I deficiency. J Clin Endocrinol Metab 1995; 80:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/36\">",
"      Peter M, Fawaz L, Drop SL, et al. Hereditary defect in biosynthesis of aldosterone: aldosterone synthase deficiency 1964-1997. J Clin Endocrinol Metab 1997; 82:3525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/37\">",
"      Nomoto S, Massa G, Mitani F, et al. CMO I deficiency caused by a point mutation in exon 8 of the human CYP11B2 gene encoding steroid 18-hydroxylase (P450C18). Biochem Biophys Res Commun 1997; 234:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/38\">",
"      Portrat-Doyen S, Tourniaire J, Richard O, et al. Isolated aldosterone synthase deficiency caused by simultaneous E198D and V386A mutations in the CYP11B2 gene. J Clin Endocrinol Metab 1998; 83:4156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/39\">",
"      Pascoe L, Curnow KM, Slutsker L, et al. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A 1992; 89:4996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/40\">",
"      Bonny O, Rossier BC. Disturbances of Na/K balance: pseudohypoaldosteronism revisited. J Am Soc Nephrol 2002; 13:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/41\">",
"      Schambelan M, Sebastian A, Rector FC Jr. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 1981; 19:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/42\">",
"      Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 1986; 8:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/43\">",
"      Take C, Ikeda K, Kurasawa T, Kurokawa K. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N Engl J Med 1991; 324:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/44\">",
"      Rossier BC. Negative regulators of sodium transport in the kidney: key factors in understanding salt-sensitive hypertension? J Clin Invest 2003; 111:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/45\">",
"      Lalioti MD, Zhang J, Volkman HM, et al. Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet 2006; 38:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/46\">",
"      Wilson FH, Kahle KT, Sabath E, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 2003; 100:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/47\">",
"      Yang CL, Angell J, Mitchell R, Ellison DH. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003; 111:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/48\">",
"      Yang CL, Zhu X, Wang Z, et al. Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. J Clin Invest 2005; 115:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/49\">",
"      Cai H, Cebotaru V, Wang YH, et al. WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. Kidney Int 2006; 69:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/50\">",
"      Wilson FH, Disse-Nicod&egrave;me S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/51\">",
"      Kahle KT, Wilson FH, Leng Q, et al. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet 2003; 35:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/52\">",
"      Choate KA, Kahle KT, Wilson FH, et al. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl- -transporting epithelia. Proc Natl Acad Sci U S A 2003; 100:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/53\">",
"      Cope G, Murthy M, Golbang AP, et al. WNK1 affects surface expression of the ROMK potassium channel independent of WNK4. J Am Soc Nephrol 2006; 17:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/54\">",
"      Ohta A, Yang SS, Rai T, et al. Overexpression of human WNK1 increases paracellular chloride permeability and phosphorylation of claudin-4 in MDCKII cells. Biochem Biophys Res Commun 2006; 349:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/55\">",
"      Bindels RJ. A molecular switch controlling renal sodium and potassium excretion. Nat Genet 2003; 35:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/56\">",
"      Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/57\">",
"      Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/58\">",
"      Vel&aacute;zquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/59\">",
"      Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/60\">",
"      Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/61\">",
"      Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/62\">",
"      Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. Gerontology 1999; 45:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/63\">",
"      Weir MA, Juurlink DN, Gomes T, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol 2010; 5:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/64\">",
"      Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010; 170:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/65\">",
"      Geller DS, Rodriguez-Soriano J, Vallo Boado A, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/66\">",
"      Tajima T, Kitagawa H, Yokoya S, et al. A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2000; 85:4690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/67\">",
"      Geller DS, Zhang J, Zennaro MC, et al. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 2006; 17:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/68\">",
"      Riepe FG, Finkeldei J, de Sanctis L, et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2006; 91:4552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/69\">",
"      Sartorato P, Lapeyraque AL, Armanini D, et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003; 88:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/70\">",
"      Sartorato P, Khaldi Y, Lapeyraque AL, et al. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Mol Cell Endocrinol 2004; 217:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/71\">",
"      Pujo L, Fagart J, Gary F, et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat 2007; 28:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/72\">",
"      Riepe FG. Clinical and molecular features of type 1 pseudohypoaldosteronism. Horm Res 2009; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/73\">",
"      Huey CL, Riepe FG, Sippell WG, Yu AS. Genetic heterogeneity in autosomal dominant pseudohypoaldosteronism type I: exclusion of claudin-8 as a candidate gene. Am J Nephrol 2004; 24:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/74\">",
"      White PC, New MI, Dupont B. Congenital adrenal hyperplasia. (1). N Engl J Med 1987; 316:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/75\">",
"      Oberfield SE, Levine LS, Carey RM, et al. Pseudohypoaldosteronism: multiple target organ unresponsiveness to mineralocorticoid hormones. J Clin Endocrinol Metab 1979; 48:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/76\">",
"      Mart&iacute;n JM, Calduch L, Monteagudo C, et al. Clinico-pathological analysis of the cutaneous lesions of a patient with type I pseudohypoaldosteronism. J Eur Acad Dermatol Venereol 2005; 19:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/77\">",
"      Sebastian A, Schambelan M, Sutton JM. Amelioration of hyperchloremic acidosis with furosemide therapy in patients with chronic renal insufficiency and type 4 renal tubular acidosis. Am J Nephrol 1984; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/44/9930/abstract/78\">",
"      Gross P, Pistrosch F. Hyperkalaemia: again. Nephrol Dial Transplant 2004; 19:2163.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2306 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9930=[""].join("\n");
var outline_f9_44_9930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2155353\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H232948\">",
"      PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233165\">",
"      Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233172\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25008898\">",
"      Reduced aldosterone production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Hyporeninemic hypoaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25009310\">",
"      Diabetes and renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25009470\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Angiotensin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147617687\">",
"      - Heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147617694\">",
"      - Primary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H232731\">",
"      - Severe illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25009618\">",
"      - Inherited disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Congenital isolated hypoaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pseudohypoaldosteronism type 2 (Gordon's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H232851\">",
"      - Genotype-phenotype correlations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H654523416\">",
"      Aldosterone resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H654523591\">",
"      - Inhibition of the epithelial sodium channel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H654523598\">",
"      Potassium-sparing diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H654523605\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H654524127\">",
"      - Pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3640046\">",
"      DIAGNOSIS OF HYPOALDOSTERONISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2155353\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19248731\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 2\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/27/37309\" title=\"figure 3\">",
"      Distal tubule transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/0/41995\" title=\"table 1\">",
"      Major causes of hypoaldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=related_link\">",
"      Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=related_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=related_link\">",
"      Patient information: Low potassium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_44_9931="Daily weight gain in infants and toddlers";
var content_f9_44_9931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected daily weight gain for children younger than three years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected weight gain, g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 3 months",
"       </td>",
"       <td>",
"        26 to 31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 6 months",
"       </td>",
"       <td>",
"        17 to 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 9 months",
"       </td>",
"       <td>",
"        12 to 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 to 12 months",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3 years",
"       </td>",
"       <td>",
"        7 to 9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Frank DA. Failure to thrive. In: The Zuckerman Parker Handbook of&nbsp;Developmental and Behavioral&nbsp;Pediatrics for Primary Care, 3rd ed,&nbsp; Augustyn M, Zuckerman B, Caronna EB&nbsp;(Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.204.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9931=[""].join("\n");
var outline_f9_44_9931=null;
var title_f9_44_9932="Cumulative incidence of PVE";
var content_f9_44_9932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated cumulative incidence of prosthetic valve endocarditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Study (years)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Initial number valve recipients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Percent of patients with PVE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"4\" rowspan=\"1\">",
"        Months after surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        12",
"       </td>",
"       <td class=\"subtitle3\">",
"        24",
"       </td>",
"       <td class=\"subtitle3\">",
"        48",
"       </td>",
"       <td class=\"subtitle3\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rutledge, et al (1985)",
"       </td>",
"       <td>",
"        1598",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ivert, et al (1984)",
"       </td>",
"       <td>",
"        1465",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calderwood, et al (1985)",
"       </td>",
"       <td>",
"        2608",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arvay &amp; Lengyel (1988)",
"       </td>",
"       <td>",
"        912",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agnihotri, et al (1995)",
"       </td>",
"       <td>",
"        2413*",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td colspan=\"1\">",
"        1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PVE: prosthetic valve endocarditis.",
"     <br>",
"      * Aortic position only.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Karchmer, AW. In: Principles and Practice of Infectious Diseases, 5th ed, Mandell, GL, et al (Eds), Churchill Livingstone, Philadelphia 1999. p. 903.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9932=[""].join("\n");
var outline_f9_44_9932=null;
var title_f9_44_9933="Infectious causes generalized lymphadenopathy children";
var content_f9_44_9933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious causes of generalized lymphadenopathy in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infectious",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected clinical features that may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein-Barr virus",
"       </td>",
"       <td>",
"        Tonsillopharyngitis, splenomegaly (&gt;50 percent), fever, malaise, fatigue; periorbital edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Fever, malaise, fatigue, occasional hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus",
"       </td>",
"       <td>",
"        Grouped vesicles; gingivostomatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus",
"       </td>",
"       <td>",
"        Generalized vesicular rash appearing in crops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus",
"       </td>",
"       <td>",
"        Respiratory tract symptoms, pharyngitis, conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubella",
"       </td>",
"       <td>",
"        Fever and rash; may be asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B virus",
"       </td>",
"       <td>",
"        High-risk sexual behavior, exposure to blood products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubeola (measles)",
"       </td>",
"       <td>",
"        Maculopapular rash with cranial to caudal progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus",
"       </td>",
"       <td>",
"        Recurrent bacterial infection, opportunistic infection, fever, diarrhea, encephalopathy, failure to thrive, hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coccidioidomycosis (valley fever)",
"       </td>",
"       <td>",
"        Pneumonia; travel to or residence in endemic area (eg, southwestern United States)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blastomycosis",
"       </td>",
"       <td>",
"        Pneumonia; travel to or residence in an endemic area (eg, southeastern and south central United States, Africa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Group A streptococcal disease",
"       </td>",
"       <td>",
"        Rash followed by desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brucellosis",
"       </td>",
"       <td>",
"        Fever, sweats, malaise, fatigue, weight loss, ingestion of unpasteurized milk; exposure to cattle, sheep, or goats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tularemia",
"       </td>",
"       <td>",
"        Fever, chills, headache; ingestion of undercooked meats, exposure to rabbits, rodents, biting flies, or mosquitoes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leptospirosis",
"       </td>",
"       <td>",
"        Fever, rigors, myalgia, headache, conjunctival injection, rash, hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Spirochetal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syphilis",
"       </td>",
"       <td>",
"        Rash, fever, malaise, anorexia, and weight loss, hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lyme disease",
"       </td>",
"       <td>",
"        Erythema migrans, fever, headache, myalgia, malaise, arthralgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasmosis",
"       </td>",
"       <td>",
"        Most infections in immunocompetent hosts are asymptomatic; myalgia, fatigue, fever, splenomegaly, and maculopapular rash may be present; exposure to cats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leishmaniasis",
"       </td>",
"       <td>",
"        Cutaneous lesions, organomegaly, fever, cachexia; exposure to sandflies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malaria",
"       </td>",
"       <td>",
"        Fever, travel to or residence in an endemic area",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.421.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9933=[""].join("\n");
var outline_f9_44_9933=null;
var title_f9_44_9934="Triple vessel coronary disease";
var content_f9_44_9934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/79485/3vescad_conv.mp4?title=Triple+vessel+coronary+disease\" style=\"width:176px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triple vessel coronary disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 176px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left coronary artery is shown in the LAO-Cranial projection. There is a severe stenosis in the circumflex artery, the proximal and mid-LAD artery and the diagonal branch. Not seen is the stenosis in the right coronary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John D. Carroll, MD. This type of movie will be part of The Multimedia Textbook of Coronary Arteriography and Interventions, Williams &amp; Wilkins, Baltimore, Fall 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9934=[""].join("\n");
var outline_f9_44_9934=null;
var title_f9_44_9935="Cryptosporidium cholangitis";
var content_f9_44_9935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptosporidium cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography in a patient with AIDS and a CD4 cell count of 30/mm3 shows sclerosing cholangitis, characterized by multiple irregular strictures throughout the medium size and large ducts, due to Cryptosporidium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vivek Raj, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_44_9935=[""].join("\n");
var outline_f9_44_9935=null;
